A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.
The veins and arteries of the HEART.
Radiography of the vascular system of the heart muscle after injection of a contrast medium.
Dilation of an occluded coronary artery (or arteries) by means of a balloon catheter to restore myocardial blood supply.
Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.
Devices that provide support for tubular structures that are being anastomosed or for body cavities during skin grafting.
Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.
Narrowing or constriction of a coronary artery.
Coagulation of blood in any of the CORONARY VESSELS. The presence of a blood clot (THROMBUS) often leads to MYOCARDIAL INFARCTION.
The circulation of blood through the CORONARY VESSELS of the HEART.
An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
The use of ultrasound to guide minimally invasive surgical procedures such as needle ASPIRATION BIOPSY; DRAINAGE; etc. Its widest application is intravascular ultrasound imaging but it is useful also in urology and intra-abdominal conditions.
An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
Stents that are covered with materials that are embedded with chemicals that are gradually released into the surrounding milieu.
Surgical therapy of ischemic coronary artery disease achieved by grafting a section of saphenous vein, internal mammary artery, or other substitute between the aorta and the obstructed coronary artery distal to the obstructive lesion.
Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.
NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
The plan and delineation of prostheses in general or a specific prosthesis.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
A family of percutaneous techniques that are used to manage CORONARY OCCLUSION, including standard balloon angioplasty (PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY), the placement of intracoronary STENTS, and atheroablative technologies (e.g., ATHERECTOMY; ENDARTERECTOMY; THROMBECTOMY; PERCUTANEOUS TRANSLUMINAL LASER ANGIOPLASTY). PTCA was the dominant form of PCI, before the widespread use of stenting.
Coumarin derivative that acts as a long acting oral anticoagulant.
Biocompatible materials usually used in dental and bone implants that enhance biologic fixation, thereby increasing the bond strength between the coated material and bone, and minimize possible biological effects that may result from the implant itself.
Elements of limited time intervals, contributing to particular results or situations.
Abnormal balloon- or sac-like dilatation in the wall of CORONARY VESSELS. Most coronary aneurysms are due to CORONARY ATHEROSCLEROSIS, and the rest are due to inflammatory diseases, such as KAWASAKI DISEASE.
Formation and development of a thrombus or blood clot in the blood vessel.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
Uncontrolled release of radioactive material from its containment. This either threatens to, or does, cause exposure to a radioactive hazard. Such an incident may occur accidentally or deliberately.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
Spasm of the large- or medium-sized coronary arteries.
Implants constructed of materials designed to be absorbed by the body without producing an immune response. They are usually composed of plastics and are frequently used in orthopedics and orthodontics.
Specific alloys not less than 85% chromium and nickel or cobalt, with traces of either nickel or cobalt, molybdenum, and other substances. They are used in partial dentures, orthopedic implants, etc.
The innermost layer of an artery or vein, made up of one layer of endothelial cells and supported by an internal elastic lamina.
The return of a sign, symptom, or disease after a remission.
The restoration of blood supply to the myocardium. (From Dorland, 28th ed)
A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.
Electropositive chemical elements characterized by ductility, malleability, luster, and conductance of heat and electricity. They can replace the hydrogen of an acid and form bases with hydroxyl radicals. (Grant & Hackh's Chemical Dictionary, 5th ed)
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
Endoscopic examination, therapy or surgery performed on the interior of blood vessels.
Complete blockage of blood flow through one of the CORONARY ARTERIES, usually from CORONARY ATHEROSCLEROSIS.
The qualitative or quantitative estimation of the likelihood of adverse effects that may result from exposure to specified health hazards or from the absence of beneficial influences. (Last, Dictionary of Epidemiology, 1988)
Obstruction of flow in biological or prosthetic vascular grafts.
Surgical insertion of BLOOD VESSEL PROSTHESES to repair injured or diseased blood vessels.
The therapy of the same disease in a patient, with the same agent or procedure repeated after initial treatment, or with an additional or alternate measure or follow-up. It does not include therapy which requires more than one administration of a therapeutic agent or regimen. Retreatment is often used with reference to a different modality when the original one was inadequate, harmful, or unsuccessful.
The condition of an anatomical structure's being constricted beyond normal dimensions.
The transference of a kidney from one human or animal to another.
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.
Surgical insertion of a prosthesis.
A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
Use of a balloon catheter for dilation of an occluded artery. It is used in treatment of arterial occlusive diseases, including renal artery stenosis and arterial occlusions in the leg. For the specific technique of BALLOON DILATION in coronary arteries, ANGIOPLASTY, BALLOON, CORONARY is available.
Precordial pain at rest, which may precede a MYOCARDIAL INFARCTION.
Methods of creating machines and devices.
A disease due to deficiency of NIACIN, a B-complex vitamin, or its precursor TRYPTOPHAN. It is characterized by scaly DERMATITIS which is often associated with DIARRHEA and DEMENTIA (the three D's).
The systems and processes involved in the establishment, support, management, and operation of registers, e.g., disease registers.
Therapy with two or more separate preparations given for a combined effect.
A method in which either the observer(s) or the subject(s) is kept ignorant of the group to which the subjects are assigned.
An antibiotic substance derived from Penicillium stoloniferum, and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase. Mycophenolic acid is important because of its selective effects on the immune system. It prevents the proliferation of T-cells, lymphocytes, and the formation of antibodies from B-cells. It also may inhibit recruitment of leukocytes to inflammatory sites. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1301)
Any of various animals that constitute the family Suidae and comprise stout-bodied, short-legged omnivorous mammals with thick skin, usually covered with coarse bristles, a rather long mobile snout, and small tail. Included are the genera Babyrousa, Phacochoerus (wart hogs), and Sus, the latter containing the domestic pig (see SUS SCROFA).
Failure of equipment to perform to standard. The failure may be due to defects or improper use.
Compounds formed by the joining of smaller, usually repeating, units linked by covalent bonds. These compounds often form large macromolecules (e.g., BIOPOLYMERS; PLASTICS).
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.
Laboratory examination used to monitor and evaluate platelet function in a patient's blood.
A CALCIUM and CALMODULIN-dependent serine/threonine protein phosphatase that is composed of the calcineurin A catalytic subunit and the calcineurin B regulatory subunit. Calcineurin has been shown to dephosphorylate a number of phosphoproteins including HISTONES; MYOSIN LIGHT CHAIN; and the regulatory subunits of CAMP-DEPENDENT PROTEIN KINASES. It is involved in the regulation of signal transduction and is the target of an important class of immunophilin-immunosuppressive drug complexes.
Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project.
Use or insertion of a tubular device into a duct, blood vessel, hollow organ, or body cavity for injecting or withdrawing fluids for diagnostic or therapeutic purposes. It differs from INTUBATION in that the tube here is used to restore or maintain patency in obstructions.
The new and thickened layer of scar tissue that forms on a PROSTHESIS, or as a result of vessel injury especially following ANGIOPLASTY or stent placement.
The hospital unit in which patients with acute cardiac disorders receive intensive care.
Malfunction of implantation shunts, valves, etc., and prosthesis loosening, migration, and breaking.
Surveillance of drugs, devices, appliances, etc., for efficacy or adverse effects, after they have been released for general sale.
Platelet membrane glycoprotein complex important for platelet adhesion and aggregation. It is an integrin complex containing INTEGRIN ALPHAIIB and INTEGRIN BETA3 which recognizes the arginine-glycine-aspartic acid (RGD) sequence present on several adhesive proteins. As such, it is a receptor for FIBRINOGEN; VON WILLEBRAND FACTOR; FIBRONECTIN; VITRONECTIN; and THROMBOSPONDINS. A deficiency of GPIIb-IIIa results in GLANZMANN THROMBASTHENIA.
Agents that prevent clotting.
VASCULAR DISEASES that are associated with DIABETES MELLITUS.
A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.
Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY.
The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
An imaging method using LASERS that is used for mapping subsurface structure. When a reflective site in the sample is at the same optical path length (coherence) as the reference mirror, the detector observes interference fringes.
An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient.
The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS.
Stainless steel. A steel containing Ni, Cr, or both. It does not tarnish on exposure and is used in corrosive environments. (Grant & Hack's Chemical Dictionary, 5th ed)
Device constructed of either synthetic or biological material that is used for the repair of injured or diseased blood vessels.
Statistical models which describe the relationship between a qualitative dependent variable (that is, one which can take only certain discrete values, such as the presence or absence of a disease) and an independent variable. A common application is in epidemiology for estimating an individual's risk (probability of a disease) as a function of a given risk factor.
Pathologic deposition of calcium salts in tissues.
Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table.
Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time.
The symptom of paroxysmal pain consequent to MYOCARDIAL ISCHEMIA usually of distinctive character, location and radiation. It is thought to be provoked by a transient stressful situation during which the oxygen requirements of the MYOCARDIUM exceed that supplied by the CORONARY CIRCULATION.
Procedures in which placement of CARDIAC CATHETERS is performed for therapeutic or diagnostic procedures.
The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065)
Surgery which could be postponed or not done at all without danger to the patient. Elective surgery includes procedures to correct non-life-threatening medical problems as well as to alleviate conditions causing psychological stress or other potential risk to patients, e.g., cosmetic or contraceptive surgery.
Migration of a foreign body from its original location to some other location in the body.
Small containers or pellets of a solid drug implanted in the body to achieve sustained release of the drug.
An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION.
The practice of replacing one prescribed drug with another that is expected to have the same clinical or psychological effect.
Drugs used to cause dilation of the blood vessels.
Coronary artery bypass surgery on a beating HEART without a CARDIOPULMONARY BYPASS (diverting the flow of blood from the heart and lungs through an oxygenator).
Establishment of the level of a quantifiable effect indicative of a biologic process. The evaluation is frequently to detect the degree of toxic or therapeutic effect.
Agents that interact with TUBULIN to inhibit or promote polymerization of MICROTUBULES.
The degree to which BLOOD VESSELS are not blocked or obstructed.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM.
Reconstruction or repair of a blood vessel, which includes the widening of a pathological narrowing of an artery or vein by the removal of atheromatous plaque material and/or the endothelial lining as well, or by dilatation (BALLOON ANGIOPLASTY) to compress an ATHEROMA. Except for ENDARTERECTOMY, usually these procedures are performed via catheterization as minimally invasive ENDOVASCULAR PROCEDURES.
A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.
Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components.
A disease characterized by the progressive invasion of SMOOTH MUSCLE CELLS into the LYMPHATIC VESSELS, and the BLOOD VESSELS. The majority of the cases occur in the LUNGS of women of child-bearing age, eventually blocking the flow of air, blood, and lymph. The common symptom is shortness of breath (DYSPNEA).
A distribution in which a variable is distributed like the sum of the squares of any given independent random variable, each of which has a normal distribution with mean of zero and variance of one. The chi-square test is a statistical test based on comparison of a test statistic to a chi-square distribution. The oldest of these tests are used to detect whether two or more population distributions differ from one another.
The physiological widening of BLOOD VESSELS by relaxing the underlying VASCULAR SMOOTH MUSCLE.
Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder.
A benign tumor containing vascular, adipose, and muscle elements. It occurs most often in the kidney with smooth muscle elements (angiolipoleiomyoma) in association with tuberous sclerosis. (Dorland, 27th ed)
Either of two large arteries originating from the abdominal aorta; they supply blood to the pelvis, abdominal wall and legs.
A value equal to the total volume flow divided by the cross-sectional area of the vascular bed.
Radiography of blood vessels after injection of a contrast medium.
Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.
The hollow, muscular organ that maintains the circulation of the blood.
Statistical models of the production, distribution, and consumption of goods and services, as well as of financial considerations. For the application of statistics to the testing and quantifying of economic theories MODELS, ECONOMETRIC is available.
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.
The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow.
Maintenance of blood flow to an organ despite obstruction of a principal vessel. Blood flow is maintained through small vessels.
Pressure, burning, or numbness in the chest.
A serine threonine kinase that controls a wide range of growth-related cellular processes. The protein is referred to as the target of RAPAMYCIN due to the discovery that SIROLIMUS (commonly known as rapamycin) forms an inhibitory complex with TACROLIMUS BINDING PROTEIN 1A that blocks the action of its enzymatic activity.
The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level.
Procedures for finding the mathematical function which best describes the relationship between a dependent variable and one or more independent variables. In linear regression (see LINEAR MODELS) the relationship is constrained to be a straight line and LEAST-SQUARES ANALYSIS is used to determine the best fit. In logistic regression (see LOGISTIC MODELS) the dependent variable is qualitative rather than continuously variable and LIKELIHOOD FUNCTIONS are used to find the best relationship. In multiple regression, the dependent variable is considered to depend on more than a single independent variable.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
A nucleoside that is composed of ADENINE and D-RIBOSE. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter.
Removal of an implanted therapeutic or prosthetic device.
PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS.
Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.
Radiographic visualization of the aorta and its branches by injection of contrast media, using percutaneous puncture or catheterization procedures.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Lesions formed within the walls of ARTERIES.
The main artery of the thigh, a continuation of the external iliac artery.
Disease having a short and relatively severe course.
A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives.
Ultrasonic recording of the size, motion, and composition of the heart and surrounding tissues. The standard approach is transthoracic.
Generally, restoration of blood supply to heart tissue which is ischemic due to decrease in normal blood supply. The decrease may result from any source including atherosclerotic obstruction, narrowing of the artery, or surgical clamping. Reperfusion can be induced to treat ischemia. Methods include chemical dissolution of an occluding thrombus, administration of vasodilator drugs, angioplasty, catheterization, and artery bypass graft surgery. However, it is thought that reperfusion can itself further damage the ischemic tissue, causing MYOCARDIAL REPERFUSION INJURY.
A tumorlike condition characterized by SMOOTH MUSCLE and ENDOTHELIUM proliferation of LYMPHATIC VESSELS and LYMPH NODES in the MEDIASTINUM and retroperitoneum, also in the lung. It may be manifested by chylous PLEURAL EFFUSION and ASCITES.
The transference of a heart from one human or animal to another.
Controlled physical activity which is performed in order to allow assessment of physiological functions, particularly cardiovascular and pulmonary, but also aerobic capacity. Maximal (most intense) exercise is usually required but submaximal exercise is also used.
Homopolymer of tetrafluoroethylene. Nonflammable, tough, inert plastic tubing or sheeting; used to line vessels, insulate, protect or lubricate apparatus; also as filter, coating for surgical implants or as prosthetic material. Synonyms: Fluoroflex; Fluoroplast; Ftoroplast; Halon; Polyfene; PTFE; Tetron.
Genetically developed small pigs for use in biomedical research. There are several strains - Yucatan miniature, Sinclair miniature, and Minnesota miniature.
The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS.
Pathological processes which result in the partial or complete obstruction of ARTERIES. They are characterized by greatly reduced or absence of blood flow through these vessels. They are also known as arterial insufficiency.
A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
The ratio of maximum blood flow to the MYOCARDIUM with CORONARY STENOSIS present, to the maximum equivalent blood flow without stenosis. The measurement is commonly used to verify borderline stenosis of CORONARY ARTERIES.
Minimally invasive procedures, diagnostic or therapeutic, performed within the BLOOD VESSELS. They may be perfomed via ANGIOSCOPY; INTERVENTIONAL MAGNETIC RESONANCE IMAGING; INTERVENTIONAL RADIOGRAPHY; or INTERVENTIONAL ULTRASONOGRAPHY.
An isoenzyme of creatine kinase found in the CARDIAC MUSCLE.
The administration of substances into the eye with a hypodermic syringe.
The relationship between the dose of an administered drug and the response of the organism to the drug.
Computed tomography where there is continuous X-ray exposure to the patient while being transported in a spiral or helical pattern through the beam of irradiation. This provides improved three-dimensional contrast and spatial resolution compared to conventional computed tomography, where data is obtained and computed from individual sequential exposures.
Persistent and reproducible chest discomfort usually precipitated by a physical exertion that dissipates upon cessation of such an activity. The symptoms are manifestations of MYOCARDIAL ISCHEMIA.
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
The transference of a part of or an entire liver from one human or animal to another.
Types of spiral computed tomography technology in which multiple slices of data are acquired simultaneously improving the resolution over single slice acquisition technology.
The vein which drains the foot and leg.
The force that opposes the flow of BLOOD through a vascular bed. It is equal to the difference in BLOOD PRESSURE across the vascular bed divided by the CARDIAC OUTPUT.
Deposition of calcium into the blood vessel structures. Excessive calcification of the vessels are associated with ATHEROSCLEROTIC PLAQUES formation particularly after MYOCARDIAL INFARCTION (see MONCKEBERG MEDIAL CALCIFIC SCLEROSIS) and chronic kidney diseases which in turn increase VASCULAR STIFFNESS.
Theoretical representations that simulate the behavior or activity of the cardiovascular system, processes, or phenomena; includes the use of mathematical equations, computers and other electronic equipment.
The hemodynamic and electrophysiological action of the left HEART VENTRICLE. Its measurement is an important aspect of the clinical evaluation of patients with heart disease to determine the effects of the disease on cardiac performance.
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
The circulation of the BLOOD through the MICROVASCULAR NETWORK.
Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.
The vessels carrying blood away from the heart.
Aneurysm caused by a tear in the TUNICA INTIMA of a blood vessel leading to interstitial HEMORRHAGE, and splitting (dissecting) of the vessel wall, often involving the AORTA. Dissection between the intima and media causes luminal occlusion. Dissection at the media, or between the media and the outer adventitia causes aneurismal dilation.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
The volume of water filtered out of plasma through glomerular capillary walls into Bowman's capsules per unit of time. It is considered to be equivalent to INULIN clearance.
Motion pictures of the passage of contrast medium through blood vessels.
The nonstriated involuntary muscle tissue of blood vessels.
An acute, febrile, mucocutaneous condition accompanied by swelling of cervical lymph nodes in infants and young children. The principal symptoms are fever, congestion of the ocular conjunctivae, reddening of the lips and oral cavity, protuberance of tongue papillae, and edema or erythema of the extremities.
An abnormal balloon- or sac-like dilatation in the wall of the THORACIC AORTA. This proximal descending portion of aorta gives rise to the visceral and the parietal branches above the aortic hiatus at the diaphragm.
An opaque, milky-white fluid consisting mainly of emulsified fats that passes through the lacteals of the small intestines into the lymphatic system.
Non-human animals, selected because of specific characteristics, for use in experimental research, teaching, or testing.
A repeat operation for the same condition in the same patient due to disease progression or recurrence, or as followup to failed previous surgery.
A genus of gram-negative, aerobic, rod-shaped bacteria in the family Sphingobacteriaceae. They exhibit gliding motility.
Body organ that filters blood for the secretion of URINE and that regulates ion concentrations.
The physiological narrowing of BLOOD VESSELS by contraction of the VASCULAR SMOOTH MUSCLE.
Hospital or other institutional committees established to protect the welfare of research subjects. Federal regulations (the "Common Rule" (45 CFR 46)) mandate the use of these committees to monitor federally-funded biomedical and behavioral research involving human subjects.
Diagnostic and therapeutic procedures that are invasive or surgical in nature, and require the expertise of a specially trained radiologist. In general, they are more invasive than diagnostic imaging but less invasive than major surgery. They often involve catheterization, fluoroscopy, or computed tomography. Some examples include percutaneous transhepatic cholangiography, percutaneous transthoracic biopsy, balloon angioplasty, and arterial embolization.
A method of computed tomography that uses radionuclides which emit a single photon of a given energy. The camera is rotated 180 or 360 degrees around the patient to capture images at multiple positions along the arc. The computer is then used to reconstruct the transaxial, sagittal, and coronal images from the 3-dimensional distribution of radionuclides in the organ. The advantages of SPECT are that it can be used to observe biochemical and physiological processes as well as size and volume of the organ. The disadvantage is that, unlike positron-emission tomography where the positron-electron annihilation results in the emission of 2 photons at 180 degrees from each other, SPECT requires physical collimation to line up the photons, which results in the loss of many available photons and hence degrades the image.
Bleeding or escape of blood from a vessel.
Arteries originating from the subclavian or axillary arteries and distributing to the anterior thoracic wall, mediastinal structures, diaphragm, pectoral muscles and mammary gland.
The presence of an increased amount of blood in a body part or an organ leading to congestion or engorgement of blood vessels. Hyperemia can be due to increase of blood flow into the area (active or arterial), or due to obstruction of outflow of blood from the area (passive or venous).
A clinical syndrome characterized by the development of CHEST PAIN at rest with concomitant transient ST segment elevation in the ELECTROCARDIOGRAM, but with preserved exercise capacity.
A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.
The dilatation of the aortic wall behind each of the cusps of the aortic valve.
Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work.
Substances used to allow enhanced visualization of tissues.
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity.
Non-invasive method of vascular imaging and determination of internal anatomy without injection of contrast media or radiation exposure. The technique is used especially in CEREBRAL ANGIOGRAPHY as well as for studies of other vascular structures.
Hydrocarbons with more than one double bond. They are a reduced form of POLYYNES.
The creation and display of functional images showing where the blood is flowing into the MYOCARDIUM by following over time the distribution of tracers injected into the blood stream.
An abnormal balloon- or sac-like dilatation in the wall of the ABDOMINAL AORTA which gives rise to the visceral, the parietal, and the terminal (iliac) branches below the aortic hiatus at the diaphragm.
A plague-like disease of rodents, transmissible to man. It is caused by FRANCISELLA TULARENSIS and is characterized by fever, chills, headache, backache, and weakness.
The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils.
Food and Drug Administration approved sirolimus-eluting coronary stents, which are used in patients with narrowing of coronary ... "CYPHER Sirolimus-eluting Coronary Stent - P020026". Food and Drug Administration. Retrieved 25 September 2012. "Torisel". ... Device profile of the Resolute Onyx Zotarolimus eluting coronary stent system for the treatment of coronary artery disease: ... Zotarolimus is an immunosuppressant used in coronary drug-eluting stents. The second generation of mTOR inhibitors is known as ...
Tissue Engineering Meets Coronary Stents." IN VIVO. London, Susan (14 November 2011). "Bioengineered, Sirolimus-Eluting Stent ... At TCT 2011, OrbusNeich's Combo Dual Therapy Stent, a coronary stent that combines the Genous technology with an ... Orbus began as a medical device company and developed the R stent, a bare-metal stent with a novel dual helix design. With the ... In 2013, OrbusNeich received CE mark for the world's first and only dual therapy stent, the COMBO Dual Therapy Stent. The COMBO ...
Food and Drug Administration approved sirolimus-eluting coronary stents, which are used in patients with narrowing of coronary ... "CYPHER Sirolimus-eluting Coronary Stent - P020026". Food and Drug Administration. Retrieved 25 September 2012.. ... Sirolimus[edit]. The bacterial natural product rapamycin or sirolimus,[6] a cytostatic agent, has been used in combination ... The structural characteristics common to temsirolimus and sirolimus; the pipecolic acid, tricarbonyl region from C13-C15, and ...
The Combo Dual Therapy Stent is a coronary stent that combines Genous with an antiproliferative, biodegradable sirolimus drug ... The Genous Stent is a bio-engineered coronary stent coated with immobilized anti-CD34 monoclonal antibodies specific to the ... "Dual-Therapy Stenting: The Next Step in the Evolution of Stent Design" Cardiology Today: Intervention "TCT: Combo Stent ... The Combo Stent was shown to be as effective as a paclitaxel-eluting stent in controlling Neointimal Hyperplasia. Bylander, ...
... low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non ... The company rose to prominence from the early success of its coronary stent line due its focus on serving the needs of the ... As of early 2018, MicroPort is one of few medical device companies still developing a commercial coronary bioresorbable stent ... safety of FIREHAWKÆ abluminal groove filled biodegradable polymer sirolimus-eluting stents for the treatment of long coronary ...
Trial to assess the use of the cYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON ...
2002 The CYPHER Sirolimus-eluting Coronary Stent, the first drug-eluting stent for patients with coronary heart disease is ... These distribution agreements are related to coronary stents and percutaneous transluminal coronary angioplasty (PTCA) balloon ... Huo Yong (霍勇)] PTCA Balloons Coronary stents Guiding catheters Diagnostic catheters Diagnostic guidewires Steerable guidewires ... 1994 Cordis receives FDA-approval for the first bare-metal stent in the US, the PALMAZ-SCHATZ Balloon-Expandable Stent for ...
"Cypher Sirolimus-eluting Coronary Stent". Cypher Stent. Archived from the original on 27 April 2003. Retrieved 1 April 2008. ... Sirolimus, also known as rapamycin, is a macrolide compound that is used to coat coronary stents, prevent organ transplant ... A sirolimus-eluting coronary stent was marketed by Cordis, a division of Johnson & Johnson, under the tradename Cypher. However ... The antiproliferative effect of sirolimus has also been used in conjunction with coronary stents to prevent restenosis in ...
CS1 maint: discouraged parameter (link) "CYPHER™ Sirolimus-eluting Coronary Stent - P020026". FDA.gov. U.S. Food and Drug ... Sirolimus: Anti-proliferative effects "Learn about CYPHER Stent, the latest advance in stent technology". Cordis Corporation. ... Cypher is a brand of drug-eluting coronary stent from Cordis Corporation, a Cardinal Health company. During a balloon ... The Cypher stent was approved for use by the FDA in 2003. Following claims of inconsistent manufacturing processes and poor ...
2003). "Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery". New England ... A drug-eluting stent (DES) is a peripheral or coronary stent (a scaffold) placed into narrowed, diseased peripheral or coronary ... such as sirolimus. Clinical trials have shown the benefits of coronary stenting with bare-metal stents over other methods of ... 2007). "Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the Ravel trial". JACC. 50 (14 ...
A dual therapy stent is a coronary artery stent that combines the technology of a bioengineered stent and a drug eluting stent ... biodegradable sirolimus drug elution. The Combo Stent has received CE Mark approval. "Dual-Therapy Stenting: The Next Step in ... Sirolimus-Eluting Stent Found 'Safe,' and 'Effective.'" Cardiology News. First Dual-Therapy Stent Nets CE Mark (Cardiology ... Dual-Therapy Stenting: The Next Step in the Evolution of Stent Design (Cardiology Today: Intervention) London, Susan (14 ...
The first two drug-eluting stents to be utilized were the paclitaxel-eluting stent and the sirolimus-eluting stent, both of ... "Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery ... Today, PCI usually includes the insertion of stents, such as bare-metal stents, drug-eluting stents, and fully resorbable ... of coronary arteries.[citation needed] Newer drug-eluting stents (DES) are traditional stents with a polymer coating containing ...
2002). "A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization". N Engl J ... "Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery". N Engl J Med. 349 (14 ... As with the Cypher stent before it, the first trials of the Taxus stent revealed no evidence of in-stent restenosis at six ... Coronary Angioplasty with Stenting versus Coronary Bypass Surgery in patients with Multiple-Vessel Disease (ERACI II): 30-day ...
... is used in drug-eluting coronary stents as an immunosuppressant to prevent restenosis. Abbott Vascular produce an ... It also may have a similar role to sirolimus in kidney and other transplants. Although, sirolimus had generated fears over use ... derivative of sirolimus and works similarly to sirolimus as an inhibitor of mammalian target of rapamycin (mTOR).[medical ... It utilizes the Multi-Link Vision cobalt chromium stent platform and Novartis' everolimus. The product is widely available ...
The first human coronary stent implantation was first performed in 1986 by Puel et al. However, there are complications ... It is a semi-synthetic derivative of sirolimus (rapamycin). It was designed for use in stents with phosphorylcholine as a ... The drug was sold/distributed to Medtronic for use on their stent platforms, which is the same drug they use today. Coronary ... Zotarolimus, or ABT-578, was originally used on Abbott's coronary stent platforms to reduce early inflammation and restenosis; ...
... a rapamycin-eluting stent, versus, a sirolimus-eluting stent (SES) and an everolimus-eluting stent (EES) and a bare metal stent ... Alvimedica is a manufacturer of coronary stents, balloon catheters, diagnostic and guiding catheters. The company was founded ... contains the main assembly of catheter and stent systems, including the first drug-eluting stent developed and manufactured in ... The company is also working on bio-degradable stents which completely dissolve in the vessel. Alvimedica sponsored a team for ...
Sirolimus eluting stents were previously used because they showed low rates of in-stent restenosis, but further investigation ... "Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis". ... In the coronary circulation, angiography of coronary artery responses to vasoactive agents may be used to test for endothelial ... It has shown an 80% sensitivity and 86% specificity to diagnose coronary artery disease when compared against the gold standard ...
... of sirolimus the S-Stent stent platform an automated stent coating technology that directly deposits the coating onto the stent ... Biosensors has set up a joint-venture with Hong Kong listed Shandong Weigao to market and distribute coronary stents in China. ... and specialty-stent providers like Devax, Inc. and Xtent, Inc. Drug-eluting stent Biolimus A9 Unknown.Biosensors and Weigao ... As one of the few companies with proprietary drug-eluting stent technology, Biosensors also has been obtaining revenue through ...
"The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes". New England Journal of Medicine. 326 (4): 242-50 ... "Bypass surgery significantly better than stents for treating multiple blockages in diabetics" (Press release). Heart.org. ... Poon, Michael; Badimon, Juan Jose; Fuster, Valentin (2002). "Viewpoint Overcoming restenosis with sirolimus: From alphabet soup ... "The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes". New England Journal of Medicine. 326 (5): 310-8 ...
"Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis". ... Stent implantation has been correlated with impaired endothelial function in several studies.[14] Sirolimus eluting stents were ... In the coronary circulation, angiography of coronary artery responses to vasoactive agents may be used to test for endothelial ... specificity to diagnose coronary artery disease when compared against the gold standard, acetylcholine angiogram.[10] This ...
Coronary Artery Disease Coronary Disease Coronary Stenosis Device: sirolimus-eluting stent Phase 3 ... Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003 Oct 2 ... Sirolimus-Eluting Stents for Chronic Total Coronary Occlusions: A Randomized Comparison of Bare Metal Stent Implantation With ... drug-eluting stent. chronic total occlusion. sirolimus-eluting stent. zotarolimus-eluting stent. QCA. ...
Plus Sirolimus-Eluting Coronary Stents by the end of 2011.. "Due to evolving market dynamics in the drug-eluting stent (DES) ... Cordis Announces Discontinuation of NEVOâ„¢ Sirolimus-Eluting Coronary Stent. Wed, 06/15/2011 - 6:33am Comments by Bio-Medicine ... Sirolimus-Eluting Coronary Stent in order to focus on other cardiovascular therapies where significant patient need exists. The ... bare metal and drug-eluting stents, carotid stenting, and treatment of peripheral vascular disease and arrhythmias. These ...
Sirolimus-eluting Coronary Stent compared with the Taxus stent in the areas of late loss, re-treatment (total lesion ... Sirolimus-eluting Coronary Stent, which is the first next generation drug-eluting stent, was launched in Europe, Asia Pacific, ... Sirolimus-eluting Coronary Stent compared with the Taxus stent in the areas of late loss, re-treatment (total lesion ... CYPHER® Sirolimus-eluting Coronary Stent benefits from clinical success, worldwide growth in 2005 Year ends with new data from ...
Plus Sirolimus-Eluting Coronary Stents by the end of 2011.. "Due to evolving market dynamics in the drug-eluting stent (DES) ... Sirolimus-Eluting Coronary Stent in order to focus on other cardiovascular therapies where significant patient need exists. The ... bare metal and drug-eluting stents, carotid stenting, and treatment of peripheral vascular disease and arrhythmias. These ... The company intends to close two manufacturing facilities: Cashel, Ireland, where the NEVO™ Stent was to be produced, and San ...
Sirolimus-eluting coronary stents. [N Engl J Med. 2004]. *Sirolimus for the prevention of in-stent restenosis in a coronary ... Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.. Moses JW1, Leon MB, ... In this randomized clinical trial involving patients with complex coronary lesions, the use of a sirolimus-eluting stent had a ... Preliminary reports of studies involving simple coronary lesions indicate that a sirolimus-eluting stent significantly reduces ...
... W.C.M. Rosa1,2, A.H. Campos1 and V.C. ... Key words: Inflammation mediators; Oral sirolimus; Percutaneous coronary intervention; Coronary artery angioplasty; Coronary ... Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356: 1030-1039. [ Links ]. ... The sirolimus-treated group (SIR-G) comprised 11 patients treated with oral sirolimus one day before and 28 days after stenting ...
Ultimaster combines an optimal balance between stent design for ult ... Comparison of sirolimus eluting stent with bioresorbable polymer to everolimus eluting stent with permanent polymer in ... stent flexibility and smooth stent-balloon transition enable ultimate stent crossability. *Low entry profile eliminates the gap ... The more complex the task, the more relevant the stent performance. *Famous Terumo hydrophilic coating on delivery system, ...
Abstract 2159: Medial Necrosis Due to Sirolimus-Eluting Stent Implantation in Human Coronary Arteries. Katsumi Inoue, Kazuaki ... Abstract 2159: Medial Necrosis Due to Sirolimus-Eluting Stent Implantation in Human Coronary Arteries ... Abstract 2159: Medial Necrosis Due to Sirolimus-Eluting Stent Implantation in Human Coronary Arteries ... Abstract 2159: Medial Necrosis Due to Sirolimus-Eluting Stent Implantation in Human Coronary Arteries ...
Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a ... The sirolimus-eluting stent is superior to the zotarolimus-eluting stent for patients receiving routine clinical care. ... compared the efficacy and safety of the zotarolimus-eluting stent versus the sirolimus-eluting stent in patients with coronary ... Sorting out drug-eluting stents. [Lancet. 2010]. *Intervention: More MACE with zotarolimus-eluting stents than with sirolimus- ...
Parallel stenting using two sirolimus-eluting stents in an ectatic coronary artery stenosis ... Parallel stenting using two sirolimus-eluting stents in an ectatic coronary artery stenosis ... coronary artery stenosis. With the introduction of the drug-eluting stent (DES), re-stenosis rates have been reduced. In ... We report a challenging case of implantation of two sirolimus-eluting stents (SES; Cypher; Cordis) parallel to each other in an ...
Sirolimus-Eluting Stent vs. Intravascular Brachytherapy in In-Stent Restenotic Coronary Artery Lesions(SISR). The safety and ... Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial ... Device: Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent ... In-Stent Restenosis Device: Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent Procedure: Brachytherapy Phase 3 ...
... and efficacy of the Supraflex sirolimus-eluting stent (SES) implantation, in de novo coronary artery disease, using clinical ... Evaluation of Clinical and Angiographic Outcomes with Biodegradable Polymer Coated Sirolimus-Eluting Stent in De Novo Coronary ... This study provides preliminary evidence for the feasibility, safety, and efficacy of the Supraflex sirolimus-eluting stent. ... Total of 66 lesions, analyzed by offline QCA, showed good scaffolding of the target vessel with in-stent late lumen loss at 9 ...
Long-term, follow-up data presented today suggest that patients who received the CYPHER Sirolimus-eluting Coronary Stent for ... blockage of a bare metal stent were significantly less lik... ... who received the CYPHER Sirolimus-eluting Coronary Stent for ... Three Year Follow-Up Data Suggest Better Outcomes Were Maintained with the Cypher Sirolimus-Eluting Coronary Stent Compared to ... The SISR Trial (A Randomized Trial Comparing Sirolimus-Eluting Stent with Vascular Brachytherapy for the Treatment of In-Stent ...
... clinicaltrials.gov The main objective of this study is to assess safety and effectiveness of double dose sirolimus-eluting Bx ... CYPHER Sirolimus-Eluting Coronary Stent, CYPHER Sirolimus-Eluting Coronary Stent. Location. Institute Dante Pazzanese of ... sirolimus eluting coronary stent in native total coronary occlusion revascularization. The pri... ... Home » Topics » Diabetes » Research » Double or Single Dose Sirolimus-Eluting Stents in Diabetic Patients With de Novo Coronary ...
Sirolimus- vs. paclitaxel-eluting stent to coronary intervention in dialysis patientsSirolimus- vs. paclitaxel-eluting stent to ... coronary intervention in dialysis patients. 透析患者におけるシロリムス溶出性ステントと
Find Sirolimus Eluting Coronary Stent System from China Manufacturer, Manufactory, Factory and Supplier - Yilson Medical ... Sirolimus Eluting Coronary Stent System Supply Ability: 80,000 Set/Sets per Month ... coating process allows the integrity of coated polymer after excessive stent expansion and a systemic elution of sirolimus in a ... This DES uses a biodegradable polymer coating on the stainless steel stent platform. The proprietary, top-quality ...
Sirolimus-Eluting Stent for the Treatment of In-Stent Restenosis. A Quantitative Coronary Angiography and Three-Dimensional ... Sirolimus-Eluting Stent for the Treatment of In-Stent Restenosis. A Quantitative Coronary Angiography and Three-Dimensional ... Sirolimus-Eluting Stent for the Treatment of In-Stent Restenosis. A Quantitative Coronary Angiography and Three-Dimensional ... Sirolimus-Eluting Stent for the Treatment of In-Stent Restenosis. A Quantitative Coronary Angiography and Three-Dimensional ...
Sirolimus-Eluting,Coronary,Stent,than,with,Taxus,Stent,in,Real-World,Clinical,Settings,medicine,advanced medical technology, ... The next version of sirolimus-eluting stent, the CYPHER(R) SELECT(TM) Sirolimus- eluting Coronary Stent, was launched in Europe ... The CYPHER(R) SELECT(TM) Plus Stent, the third version of a sirolimus-eluting coronary stent, received CE Mark in 2006 and is ... New Study Suggests Better Patient Outcomes with CYPHER,Sirolimus-Eluting Coronary Stent than with Taxus Stent in,Real-World ...
Right coronary artery diverticulosis 4 years after sirolimus-eluting stent implantation associated with very late stent ... Right coronary artery diverticulosis 4 years after sirolimus-eluting stent implantation associated with very late stent ... Right coronary artery diverticulosis 4 years after sirolimus-eluting stent implantation associated with very late stent ...
... durable polymer sirolimus-eluting stent); group 2, Cypher Redox® (3.1 µg sirolimus/mm, durable polymer sirolimus-eluting stent ... Comparison of vascular response to different doses and patterns of elution of sirolimus-eluting stents using coronary ... polymer-free sirolimus-eluting stent). RESULTS: In the 10 ± 1 month followup, Cypher®, Redox® and VESTAsyncTM stents showed a ... Keywords : Drug-eluting stents; Sirolimus; Ultrasonography, interventional. · abstract in Portuguese · text in Portuguese · ...
The utilization of the sirolimus-eluting stent for percutaneous intervention in a high-risk population with a history of ... Effectiveness of the sirolimus-eluting stent in the treatment of patients with a prior history of coronary artery bypass graft ... Conclusions: The utilization of the sirolimus-eluting stent for percutaneous intervention in a high-risk population with a ... We evaluated the impact of utilizing the sirolimus-eluting stent (SES) in this high-risk population. ...
Drug eluting stents: Focus on Cypher™ sirolimus-eluting coronary stents in the treatment of patients with bifurcation lesions. ... Furthermore, although the "provisional" stenting technique (second stent on the SB placed, after the MB stenting, only in case ... Regardless of the stenting technique used, however, restenosis rate after bare metal stent (BMS) is high, especially at the ... Finally, the introduction of dedicated stents for different types of bifurcations, with specific stent designs to provide good ...
2003) Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349: ... 2002) A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med ... Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis. Comparison with bare metal stent ... Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis. Seung-Jung Park, Young-Hak Kim, Bong- ...
10-Year Clinical Outcome After Randomization to Treatment by Sirolimus- or Paclitaxel-Eluting Coronary Stents. In: Journal of ... 10-Year Clinical Outcome After Randomization to Treatment by Sirolimus- or Paclitaxel-Eluting Coronary Stents. Journal of the ... 10-Year Clinical Outcome After Randomization to Treatment by Sirolimus- or Paclitaxel-Eluting Coronary Stents. / Galløe, Anders ... title = "10-Year Clinical Outcome After Randomization to Treatment by Sirolimus- or Paclitaxel-Eluting Coronary Stents", ...
2003) Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349: ... 2002) A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med ... 2001) Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 104:1188-1193. ... 2004) Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res 63 ...
Acute Coronary Syndrome due to Early Multiple and Complete Fractures in Sirolimus-Eluting Stent: A Case Report and Brief ... Despite drug eluting stents (DES), as compared to bare metal stents, have reduced in-stent restenosis, complex and long lesions ... We reported a case of 69 years old man with rare early and complex DES fractures on right coronary that caused acute coronary ... Their treatment is often associated with an unfavorable outcome, related to in-stent restenosis, stent thrombosis, and target ...
In addition, lower rates of death (RR: 0.91; 95% CI: 0.83-1.00), any stent thrombosis (RR: 0.62; 95% CI: 0.45-0.86), definite ... Lower rates of death and stent thrombosis were also observed in observational studies in SES-treated patients. ... stent thrombosis, major adverse cardiac events (MACEs), restenosis and late lumen loss. Results Seventy-six studies including ... compared with paclitaxel-eluting stents (PES, Taxus) in large head-to-head comparisons still remain to be defined. Methods We ...
minimally invasive direct coronary artery bypass. PCI. percutaneous coronary intervention. SES. sirolimus-eluting stent(s). SF- ... 2011) Sirolimus-eluting stent implantation for ostial left anterior descending coronary artery lesions: three-year outcome from ... 2009) Randomized comparison of minimally invasive direct coronary artery bypass surgery versus sirolimus-eluting stenting in ... IQR = interquartile range; MIDCAB = minimally invasive direct coronary artery bypass surgery; SES = sirolimus-eluting stent(s). ...
Sirolimus-Eluting Coronary Stent Compared With a Cobalt-Chromium Everolimus-Eluting Stent in Patients With Acute Coronary ... Sirolimus-Eluting Coronary Stent Compared With a Cobalt-Chromium Everolimus-Eluting Stent in Patients With Acute Coronary ... The primary endpoint was the percentage of uncovered stent struts per stent. Stent assessment by optical coherence tomography ... The primary endpoint was the percentage of uncovered stent struts per stent. Stent assessment by optical coherence tomography ...
... coronary artery stent (MIV Therapeutics, Inc.) is the new-generation variable geometry stent designed to minimize stent-induced ... 2007) Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356:998-1008. ... drug-eluting stent. IVUS. intravascular ultrasound. QCA. quantitative coronary angiography. VES. Vestasync-eluting stent. ... 2004) Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? ...
  • Primary intracoronary stent placement after successfully crossing chronic total occlusions (CTO) decreases the high restenosis rate at long-term follow-up compared with conventional balloon angioplasty. (clinicaltrials.gov)
  • Since data from the 2 landmark studies, the BENESTENT and STRESS studies, showed that coronary stenting significantly decreases restenosis as compared with conventional balloon angioplasty, this treatment modality has shown to be superior in an increasing number of indications. (clinicaltrials.gov)
  • Percutaneous coronary intervention of chronic total occlusions (CTO), however, is still limited by high restenosis rates. (clinicaltrials.gov)
  • In 200 patients with CTO randomized in the PRISON I study, we demonstrated a restenosis rate of 22% after bare metal stent implantation as compared with 33% after conventional balloon angioplasty. (clinicaltrials.gov)
  • During the past few years, sirolimus (rapamycin), a cytostatic macrocyclic lactone with anti-inflammatory and antiproliferative properties, delivered from a polymer-encapsulated stent was shown to almost eliminate the risk of restenosis in selected groups of patients. (clinicaltrials.gov)
  • New data from a Spanish study presented at the 2005 American Heart Association Scientific Sessions found that patients with bifurcation lesions fared significantly better when treated with the CYPHER® Sirolimus-eluting Coronary Stent compared with the Taxus stent in the areas of late loss, re-treatment (total lesion revascularization or TLR) and re-blockage (restenosis). (eurekalert.org)
  • The 205-patient, randomized, comparative clinical trial found that at six months, patients with bifurcations in the CYPHER® Stent arm were three times less likely to experience restenosis (9 percent for CYPHER® Stent vs. 29 percent for Taxus stent, p=0.05) and undergo TLR (4 percent for CYPHER® Stent vs. 13 percent for Taxus stent, p=0.05) than patients with bifurcations in the Taxus stent arm of the study. (eurekalert.org)
  • In 2005, the SIRTAX study, published in the NEJM, found statistically significant differences favoring the CYPHER® Stent compared with the Taxus stent across a variety of measures, including major cardiac adverse events (MACE), TLR, in-segment late loss and in-segment binary restenosis. (eurekalert.org)
  • Preliminary reports of studies involving simple coronary lesions indicate that a sirolimus-eluting stent significantly reduces the risk of restenosis after percutaneous coronary revascularization. (nih.gov)
  • In this randomized clinical trial involving patients with complex coronary lesions, the use of a sirolimus-eluting stent had a consistent treatment effect, reducing the rates of restenosis and associated clinical events in all subgroups analyzed. (nih.gov)
  • Sirolimus for the prevention of in-stent restenosis in a coronary artery. (nih.gov)
  • We studied the effect of oral sirolimus, administered to prevent and treat in-stent restenosis (ISR), on the variation of serum levels of inflammatory markers following coronary stenting with bare metal stents. (scielo.br)
  • It is well known that coronary artery angioplasty and stenting are both associated with local vascular and systemic inflammation (1-4), which in turn correlate with increased restenosis after percutaneous coronary interventions (PCI) (5-7). (scielo.br)
  • However, the nature of the inflammatory response to coronary artery stenting is different from that associated with balloon angioplasty, and the specific biological response to stent injury is strongly associated with intimal smooth muscle cell migration/proliferation that culminates in in-stent restenosis (ISR) (8). (scielo.br)
  • Background: Sirolimus-eluting stents (SES) have been proven to reduce the rates of restenosis by a striking inhibition of neointimal hyperplasia. (ahajournals.org)
  • In low-risk patients, the zotarolimus-eluting stent has been shown to reduce rates of restenosis without increasing the risk of stent thrombosis. (nih.gov)
  • Angiographic in-lesion and in-stent binary restenosis (³ 50% diameter stenosis) at 6 months post-procedure (by QCA). (clinicaltrials.gov)
  • The SISR Trial (A Randomized Trial Comparing Sirolimus-Eluting Stent with Vascular Brachytherapy for the Treatment of In-Stent Restenosis Within Bare Metal Stents) is a multi-center, randomized study of 384 patients from 26 academic and community health centers in the United States. (webwire.com)
  • p=0.067) and major adverse cardiac events, also known as MACE, were both improved with the CYPHER Stent, this did not reach statistical significance, likely reflecting progression of coronary artery disease at sites other than the original location of bare metal stent restenosis. (webwire.com)
  • The CYPHER Stent does not have an approved indication for the treatment of in-stent restenosis in the United States. (webwire.com)
  • Chronic total coronary occlusions (CTO) have an especially high risk of angiographic restenosis, and need for new revascularization procedures. (bioportfolio.com)
  • Sirolimus-Eluting Stent for the Treatment of In-Stent Restenosis. (ahajournals.org)
  • Conclusions Sirolimus-eluting stent implantation for unprotected LMCA stenosis appears safe with regard to acute and midterm complications and is more effective in preventing restenosis compared to BMS implantation. (onlinejacc.org)
  • In-stent restenosis is the main limit to the long-term efficacy of coronary stenting and may be associated with increased long-term mortality of unprotected LMCA intervention ( 5 ). (onlinejacc.org)
  • The sirolimus-eluting stent (SES) (Cypher, Cordis, Johnson and Johnson Corp, Miami, Florida) markedly decreases in-stent restenosis in elective patients with relatively simple coronary lesions ( 9,10 ). (onlinejacc.org)
  • Regardless of the stenting technique used, however, restenosis rate after bare metal stent (BMS) is high, especially at the ostium of the side branch (SB). (dovepress.com)
  • The introduction of drug-eluting stent (DES) has remarkably improved the outcome in bifurcation lesions compared to BMS, resulting in lower adverse events and main branch (MB) restenosis rates. (dovepress.com)
  • Despite drug eluting stents (DES), as compared to bare metal stents, have reduced in-stent restenosis, complex and long lesions remains a challenge for interventional cardiologist. (ovid.com)
  • Their treatment is often associated with an unfavorable outcome, related to in-stent restenosis, stent thrombosis, and target lesion revascularization. (ovid.com)
  • This study sought to compare the 1-year safety and efficacy of Cypher Select or Cypher Select Plus (Cordis Corporation, Bridgewater, New Jersey) sirolimus-eluting stents (SES) with the treatment of bare-metal stents (BMS) and drug-eluting stent (DES) in-stent restenosis (ISR) in nonselected, real-world patients. (elsevier.com)
  • XPLOSION+™ takes the ideal definition of Safety - Efficiency - Deliverability for Percutaneous Coronary Intervention (PCI) to a higher level, convinces with its trusted technology and largest size portfolio available provides high end performance with less metallic coverage but reliable outcomes, and offers an optimal solution for improving luminal diameter and reducing in-stent restenosis when treating coronary artery lesions. (com.vn)
  • Background - The use of sirolimus-eluting coronary stents has been associated with a nearly complete elimination of restenosis at 6 months and with a very low 1-year incidence of major adverse cardiac events (MACE). (elsevier.com)
  • The introduction of drug-eluting stents (DES) led to a significant decrease in angiographic and clinical restenosis by inhibiting smooth muscle cell migration and proliferation compared with bare-metal stents [ 1 - 4 ]. (kjim.org)
  • In addition, a number of studies indicated that both sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) significantly decreased the rate of angiographic restenosis despite differences in late loss [ 3 - 6 ]. (kjim.org)
  • Cypher) have demonstrated a significant reduction in restenosis rates when compared to bare metal stents (BMSs). (elsevier.com)
  • Intracoronary stents are widely regarded as a major therapeutic advance in cardiology because they reduce the rate of angiographic restenosis and subsequent need for repeated percutaneous coronary intervention (PCI). (acpjc.org)
  • The higher upfront cost of stenting is outweighed by the benefit of reducing risk for restenosis and associated costs of repeated PCI. (acpjc.org)
  • From a recent study, the sirolimus eluting stent (SES) (CYPHER, Cordis, Johnson & Johnson) appear to demonstrate a remarkable efficacy and safety in preventing restenosis. (bvsalud.org)
  • Drug-eluting stents (DES) were developed in the early 2000's to reduce restenosis (ie, recurrent narrowing) rates in stented coronary lesions. (medscape.com)
  • [ 2 , 3 ] There was significant improvement in angiographic results (in stent late lumen loss: 0.17 mm vs 1.00 mm) as well as clinical outcomes (binary in-lesion restenosis: 8.9% vs 36.3%) in the sirlolimus stent treatment group relative to the BMS group. (medscape.com)
  • [ 4 ] Restenosis remains an issue in coronary drug-eluting stent implantation for ostial RCA lesions. (medscape.com)
  • In spite of its great success in reducing restenosis, drug-eluting stent (DES) has unfavorable aspects such as stent thrombosis and delayed re-endothelialization. (nature.com)
  • Drug-eluting stents (DES) using anti-proliferative agents such as rapamycin or paclitaxel, have become the most promising method to prevent restenosis after percutaneous coronary intervention (PCI) 1 , 2 . (nature.com)
  • This suggests that PKG plays an important role in modulating the VSMC phenotype and neointimal formation, which are associated with restenosis after stent implantation. (nature.com)
  • The antiproliferative effect of sirolimus has also been used in conjunction with coronary stents to prevent restenosis in coronary arteries following balloon angioplasty. (wikipedia.org)
  • Several large clinical studies have demonstrated lower restenosis rates in patients treated with sirolimus-eluting stents when compared to bare-metal stents, resulting in fewer repeat procedures. (wikipedia.org)
  • Both early complications such as elastic recoil and acute vessel occlusion, as well as late restenosis from negative remodeling and to a lesser extent intimal hyperplasia, led to the development of stents made of bare metal (BMS), initially stainless steel, and later cobalt chromium alloys. (hindawi.com)
  • In contrast to balloon angioplasty, the phenomenon of "in-stent" restenosis is known to be caused by excessive neointimal proliferation at the site of the vessel injury, with little late vessel/stent recoil. (hindawi.com)
  • First generation DES effectively reduced in-stent restenosis, but profoundly delay healing and are susceptible to late stent thrombosis, leading to significant clinical complications in the long term. (mdpi.com)
  • This review characterizes the development of coronary stents, detailing the incremental improvements, which aim to attenuate the major clinical complications of thrombosis and restenosis. (mdpi.com)
  • Drug-eluting stents have limited restenosis and reintervention but are complicated by late and very late thrombosis and accelerated neoatherosclerosis. (nih.gov)
  • 13 Nevertheless, according to the manufacturers, this excess risk is not associated with an increased risk of myocardial infarction or cardiovascular death - instead, the increased risk of adverse conseqences due to late stent thrombosis is balanced by a corres-ponding reduction in risk due to a reduced rate of restenosis and a reduced need for further intervention. (mja.com.au)
  • 13 Restenosis is a far less serious complication than stent thrombosis, but nevertheless carries approximately a 10% risk of causing myocardial infarction. (mja.com.au)
  • Cardiology A clinical trial-Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions Conclusion The treated stent effectively prevents neointimal proliferation, restenosis, and associated clinical events. (thefreedictionary.com)
  • Percutaneous coronary interventions (PCIs) using drug-eluting stents (DESs) are credited with significant reductions in vessel restenosis, due to the effective combination of a drug delivery system and mechanical scaffold ( 1 ). (pnas.org)
  • Drug-eluting stents allowed considerable reduction in the risk of restenosis and repeat interventions while encouraging the development of numerous complex techniques permitting complete bifurcation coverage. (springer.com)
  • Data from the British Columbia Cardiac Registries during the mid-1990s show that restenosis occurs in about 15% of patients with stents. (cmaj.ca)
  • Sirolimus is an immunosupressant agent that is believed to prevent restenosis, probably by inhibition of cytokine-mediated and growth-factor-mediated proliferation of lymphocytes and smooth-muscle cells. (cmaj.ca)
  • The stent is not indicated for the treatment of restenosis. (cmaj.ca)
  • The in-stent percent diameter stenosis and the binary restenosis rate of the two treatment arms were similar (19.2±12.0% vs. 16.1±12.6%, p=0.09, and 3.3% vs. 4.4%, p=1.00, respectively). (eur.nl)
  • drug -eluting stent (DES) implantation significantly reduced the neointimal hyperplasia and angiographic restenosis compared to BMS in diabetic patients (3), presence of diabetes mellitus (DM) have been still associated with an increased risk of restenosis and unfavorable clinical outcomes in the era of DES (4,5). (bioportfolio.com)
  • The stent is designed to release rapamycin to prevent restenosis, but unlike similar stents the crystalline drug stays within the nearby tissue for months after the coating and polymer surrounding the cobalt chromium metal stent have been absorbed. (medgadget.com)
  • Diabetic patients often have hypertriglyceridemia with elevated levels of VLDL cholesterol but normal levels of low-density lipoprotein cholesterol (LDL-C). The aim of the present study was to elucidate the potential role of remnant lipoproteins-induced atherosclerosis in the occurrence and development of in-stent restenosis (ISR) in diabetic patients with coronary artery disease. (springer.com)
  • Physicians should take measures to control RLP-C below the level of 0.505 mmol/L to better prevent of in-stent restenosis in diabetic patients. (springer.com)
  • In-stent restenosis is an important factor for successful underwent percutaneous coronary intervention (PCI). (springer.com)
  • In a patient population with minimal exclusion criteria and using late lumen loss (LLL) as an early and robust marker for restenosis, bioresorbable vascular scaffold (BVS) demonstrates "satisfactory angiographic and clinical outcomes" compared to everolimus-eluting stents (EES) and biolimus-eluting stents (BES), according to results of the EVERBIO II trial presented Sept. 16 at TCT 2014. (acc.org)
  • Percutaneous transluminal coronary angioplasty (PTCA) has greatly benefited patients with occluded coronary arteries, but its benefits have been undermined by a high incidence of restenosis. (aspetjournals.org)
  • The introduction of coronary stents has significantly improved the short and long term outcome but restenosis still occurs in approximately 15 to 30% of patients within 6 months. (aspetjournals.org)
  • Prevention of restenosis after successful PTCA remains one of the most challenging tasks in the treatment of obstructive coronary artery disease. (aspetjournals.org)
  • This incidence of in-stent restenosis is expected to increase as coronary stenting is becoming more frequent and is used in less ideal lesions. (aspetjournals.org)
  • 5 Although both types of stents, drug-eluting or not, can reduce restenosis risk and subsequent revascularization, DES prevent restenosis more effectively. (pharmacytimes.com)
  • Any patient who receives a DES instead of a BMS is at a higher risk for late stent thrombosis (albeit at a lower risk for restenosis). (pharmacytimes.com)
  • The impact of stent geometry on restenosis and strategies to deal with challenging lesions such as bifurcations and lesions in the left main stem are also discussed. (portlandpress.com)
  • Traditional coronary stents are bare-metal (usually stainless-steel) cages that scaffold the artery, stabilize the plaque and help to prevent arterial recoil and therefore restenosis. (portlandpress.com)
  • BENESTENT 1 and STRESS, two early but significant clinical trials, clearly showed that stenting in native vessels reduced the incidence of restenosis compared with PTCA alone [ 3 , 4 ]. (portlandpress.com)
  • The unanswered question is whether the decrease in risk for death and MI from avoiding CABG, restenosis, or repeated PCI is greater than the risk for death or MI from late stent thrombosis. (acpjc.org)
  • In-stent restenosis and stent thrombosis remain clinically significant problems for bifurcation lesions. (royalsocietypublishing.org)
  • Restenosis after percutaneous coronary intervention is a significant clinical problem, occurring after 15% to 30% of angioplasty procedures or intracoronary stenting. (ahajournals.org)
  • 1,2 ⇓ Recent evidence has demonstrated that treatment with the immunosuppressive agent rapamycin (also known as sirolimus) dramatically reduces in-stent restenosis. (ahajournals.org)
  • Initial encouraging results in both canine and porcine models 3 have been borne out in human studies in which rapamycin, delivered via drug-coated stents, led to restenosis rates near zero after 4 months and 1 year. (ahajournals.org)
  • One month follow-up C-reactive protein may be a useful predictor of angiographic restenosis and long-term clinical outcomes after bare metal stent implantation. (thefreedictionary.com)
  • Clinical data from the Horizons-AMI trial showed that, in patients with AMI, paclitaxel-eluting stents were superior in efficacy to bare-metal stents, significantly reducing clinical and angiographic restenosis compared to bare-metal stents, while demonstrating a comparable safety profile at three years. (thefreedictionary.com)
  • 01mm), a binary angiographic restenosis rate of 0%, and no acute or late stent thrombosis. (thefreedictionary.com)
  • Stone, a professor of medicine at Columbia University Medical Center/New York-Presbyterian Hospital, has revealed that in patients undergoing angioplasty, the use of paclitaxel-eluting stents has been found to reduce rates of target lesion revascularization (TLR) and binary angiographic restenosis when compared to the use of bare-metal stents after 1 year. (thefreedictionary.com)
  • Predictors of angiographic restenosis after stenting: Pooled analysis of 1197 patients with protocol-mandated angiographic follow-up from five randomized stent trials. (thefreedictionary.com)
  • HORIZONS-AMI demonstrated that the TAXUS Express Stent significantly reduced clinical and angiographic restenosis compared to an otherwise identical bare-metal Express control stent. (thefreedictionary.com)
  • Heme oxygenase-1 gene promotor microsatellite polymorphism is associated with angiographic restenosis after coronary stenting. (thefreedictionary.com)
  • Patients who received sirolimus-eluting stents also had significantly less angiographic restenosis compared with those who got paclitaxel-eluting stents, 6. (thefreedictionary.com)
  • ABSTRACT: Drug-eluting stents (DES) have been shown to significantly reduce the incidence of restenosis and target lesion revascularization in a wide variety of clinical situations. (invasivecardiology.com)
  • This is usually an acute process in contrast to restenosis, which is a gradual narrowing of the stent lumen due to neointimal proliferation. (oncologynurseadvisor.com)
  • Stent thrombosis often results in an acute coronary syndrome, while restenosis often results in anginal symptoms. (oncologynurseadvisor.com)
  • In-stent restenosis (i.e., neointimal proliferation) can be seen after percutaneous coronary intervention. (oncologynurseadvisor.com)
  • In-stent restenosis usually presents as an insidious process in which patients have a gradual escalation of anginal symptoms 6 to 12 months after their index procedure. (oncologynurseadvisor.com)
  • Use of sirolimus-eluting stents in percutaneous coronary intervention (PCI) has markedly reduced the rates of restenosis and repeat intervention. (medpagetoday.com)
  • In addition, there were no significant differences in safety endpoints, such as the rates of death, myocardial infarction (MI), or stent thrombosis between the two treatment arms of this study. (webwire.com)
  • This longer-term, follow-up analysis focused on pre-specified safety endpoints, namely death, MI and stent thrombosis, as well as target lesion revascularization (TLR), an efficacy endpoint, to determine whether any new safety issues emerged and whether the major benefit of the CYPHER Stent, namely reduction in TLR, was maintained. (webwire.com)
  • There were no incidents of death, stent thrombosis, Q-wave myocardial infarction (MI), or emergent bypass surgery during hospitalization in either group. (onlinejacc.org)
  • No target vessel stent thrombosis has been documented within 540 days. (uzh.ch)
  • Synthetic polymers have been associated with intensive inflammatory response and late stent thrombosis. (onlinejacc.org)
  • Objectives: The aim of this study was to ascertain the 1-year incidence of stent thrombosis (ST) and major bleeding (MB) in a large, unselected population treated with sirolimus-eluting stents (SES). (elsevier.com)
  • Background: Stent thrombosis and MB are major potential complications of drug-eluting stent implantation. (elsevier.com)
  • Stent thrombosis and MB very rarely occurred in the same patient. (elsevier.com)
  • Primary endpoint was major adverse cardiac events and stent thrombosis rate at 1 year. (elsevier.com)
  • At 1 year, death (1.4% for BMS vs. 2.1% for DES, p = 0.3) and myocardial infarction (2.4% for BMS and 3.3% for DES, p = 0.3) rates were similar, whereas ischemia-driven target lesion revascularization and definite/probable late stent thrombosis were higher in patients with DES ISR (6.9% vs. 3.1%, p = 0.003, and 1.8% vs. 0.5%, p = 0.04, respectively). (elsevier.com)
  • The effective inhibition of in-stent neointima formation by the first-generation DESs may reduce neointimal coverage of stents, leaving stent struts as a nidus for late stent thrombosis. (biomedcentral.com)
  • Late stent thrombosis has also been associated with late-acquired malapposition of stent struts [ 8 ] and late vascular inflammation (beyond that associated with the initial vascular injury and subsequent healing) [ 9 ], both of which may be related to either the type of drug eluted or the polymer coating of the stents. (biomedcentral.com)
  • Findings from randomised studies, the largest being the Danish Organisation for Randomized Trials with Clinical Outcome (SORT OUT) III trial, indicated that ZES, as compared to SES, had lower efficacy and was associated with increased risk of early stent thrombosis and all-cause mortality. (biomedcentral.com)
  • Stent thrombosis in randomized clinical trials of drug-eluting stents. (naver.com)
  • Meta-analysis showed that groups did not differ for all-cause death, stent thrombosis (overall), or the composite endpoint of death or MI (Table). (acpjc.org)
  • After 1 year, SESs increased risk for stent thrombosis more than did BMSs (0.6% vs 0.05%, P = 0.02). (acpjc.org)
  • however, while the study reduces overall concerns of increased events with DESs, the increase in late stent thrombosis and the apparent lack of benefit in patients with diabetes remain issues of concern. (acpjc.org)
  • During one-year follow-up after IVUS examination, the rate of very late stent thrombosis tended to be higher in patients with than in those without late ISA (18.7% vs 3.3%, P = 0.051). (bvsalud.org)
  • Late ISA tended to increase the rate of very late stent thrombosis during follow-up, highlighting the importance of long-term dual antiplatelet therapy for these patients . (bvsalud.org)
  • In addition, if a drug could also inhibit platelet aggregation, it would be very helpful because it prevents stent thrombosis associated with DES 10 . (nature.com)
  • Thus, we can assume that drugs that modulate PKG activity could be used as a candidate drug for DES without increasing stent thrombosis. (nature.com)
  • However, this kind of stent may also increase the risk of vascular thrombosis. (wikipedia.org)
  • The complication of stent thrombosis (ST) emerged at a rate of 0.5% annually for first-generation drug-eluting stents (DES), often presenting as death or myocardial infarction. (hindawi.com)
  • This review will focus on a specific clinical and anatomic subset of coronary thrombosis that can lead to MI and SCD of thrombotic occlusion of a previously-stented coronary artery (stent thrombosis, ST) [ 4 - 6 ]. (hindawi.com)
  • No cases of definite stent thrombosis were reported in the Combo group. (nih.gov)
  • Unlike the animal models in which they were tested, 5 in the human atherosclerotic coronary artery, the drugs markedly inhibit or delay endothelialisation of the stent struts, 6 , 7 thus making the stent more susceptible to thrombosis, particularly if dual antiplatelet therapy with aspirin and clopidogrel is interrupted after implantation. (mja.com.au)
  • 9 , 10 Opinion varies on the relative susceptibility of DES and BMS to thrombosis, but based on their personal experience, many cardiologists worldwide are convinced that the incidence of late stent thrombosis (ie, more than 30 days post-implantation) is higher with DES. (mja.com.au)
  • 11 , 12 Nor was there any apparent increased risk of stent thrombosis with DES. (mja.com.au)
  • However, 4-year follow-up data recently released by the stent manufacturers now indicate a higher rate of stent thrombosis with DES compared with BMS (1.3% v 0.8% for the paclitaxel-eluting stent, and 1.2% v 0.6% for the sirolimus-eluting stent). (mja.com.au)
  • The likelihood of stent thrombosis is undoubtedly higher in more complex coronary lesions, and therefore any increased tendency towards stent thrombosis with use of DES is likely to be accentuated. (mja.com.au)
  • Recently presented data from a large European registry where off-label use was common indicate a 0.6% per annum increase in late stent thrombosis with use of DES, compared with BMS. (mja.com.au)
  • 16 Whether this higher incidence of stent thrombosis translates into a higher rate of myocardial infarction or death in comparison to alternative treatments, such as BMS or coronary artery bypass surgery, has not been tested in randomised studies. (mja.com.au)
  • IVUS Findings in Late and Very Late Stent Thrombosis. (revespcardiol.org)
  • Stent thrombosis (ST) is a life-threatening complication after stent implantation. (revespcardiol.org)
  • These numerically lower rates of cardiac death, Q-wave myocardial infarction and stent thrombosis favoring the CYPHER Stent were also seen in diabetic patients who required insulin therapy. (webwire.com)
  • Early experience with the CYPHER stent has shown that stent thrombosis occurs in 0.5% of patients. (cmaj.ca)
  • Since the product was approved in the United States, the FDA has received 47 reports of stent thrombosis that occurred at the time of implantation or within a few days of implantation. (cmaj.ca)
  • 5 Although it is unclear whether the rate of stent thrombosis that is being detected in clinical practice is higher than that observed in the pre-approval clinical trials, the manufacturer issued a warning letter to US physicians on July 7. (cmaj.ca)
  • High grade lesions, lesions with significant clot, inflammation or lipid content are at an even greater risk of stent thrombosis. (plos.org)
  • Definite stent thrombosis (ARC-defined) occurred in 0.3% (4/1,172), 0.3% (4/1,169) and 0.3% (3/1173) of patients, respectively (logrank-P=0.70 for both main comparisons). (crf.org)
  • Spearheaded by principal investigator Stéphane Cook, MD, University and Hospital Fribourg, Switzerland, the trial sought to assess the efficiency and safety of the Absorb bioresorbable vascular scaffold and its ability to reduce long-term complications such as neoatherosclerosis and very late stent thrombosis. (acc.org)
  • A relatively uncommon adverse event, stent thrombosis, occurs in about 0.6% of patients per year. (pharmacytimes.com)
  • 6 Stent thrombosis is the formation of a clot at the site of stent placement. (pharmacytimes.com)
  • 10 Stent thrombosis usually occurs early (within 30 days of stent placement) or late (more than 1 year after stent placement). (pharmacytimes.com)
  • When the FDA first approved DES on the basis of 9-month clinical trials, the risk of stent thrombosis did not appear to be increased, compared with the risk with BMS. (pharmacytimes.com)
  • 6,7 Recent postmarket surveillance studies, however, suggest that the risk of late stent thrombosis with DES is increased, compared with that of BMS. (pharmacytimes.com)
  • One proposed mechanism for the increased late stent thrombosis with DES is that the sirolimus or paclitaxel prevents the DES from becoming endothelialized, or covered with endothelial cells, soon after placement. (pharmacytimes.com)
  • So, whereas the risk of stent thrombosis with BMS decreases after 30 days, the risk remains high with DES. (pharmacytimes.com)
  • 12 Recent studies have shown that patients with off-label indications have more than double the risk of early and late stent thrombosis, compared with patients with less complex disease. (pharmacytimes.com)
  • 15 Recent analyses indicate that 29% of patients who discontinue thienopyridine therapy prematurely experience stent thrombosis, and early discontinuers have 9 times the risk of death in the first year following stent placement. (pharmacytimes.com)
  • The goal of the study was to evaluate stent thrombosis among patients undergoing percutaneous coronary intervention (PCI) with bare-metal stents (BMS) compared with drug-eluting stents (DES). (acc.org)
  • Endpoints evaluated were stent thrombosis, death, Q-wave myocardial infarction (MI), and the composite of death or Q-wave MI. (acc.org)
  • Among the SES trials, total stent thrombosis occurred in 1.2% of SES patients and 0.6% of BMS patients (relative risk [RR] 2.0, p = 0.20). (acc.org)
  • Late stent thrombosis (occurring ≥1 year) was significantly higher with SES versus BMS (0.6% vs. 0%, p = 0.025). (acc.org)
  • Among the PES trials, total stent thrombosis occurred in 1.3% of PES patients and 0.9% of BMS patients (RR 1.44, p = 0.30). (acc.org)
  • Late stent thrombosis (occurring ≥1 year) was significantly higher with PES versus BMS (0.7% vs. 0.2%, p = 0.028). (acc.org)
  • Among patients undergoing PCI for de novo coronary lesions, DES were associated with significantly higher rates of late stent thrombosis but no excess in mortality compared with BMS in this patient-level analysis of nine trials of the PES and SES. (acc.org)
  • Given the large number of patients treated with DES annually (estimated at ~1 million per year), even a small excess in stent thrombosis with DES can have large, long-term clinical implications. (acc.org)
  • Total, cardiac, and noncardiac mortality and stent thrombosis. (acpjc.org)
  • 30 d) stent thrombosis (Table). (acpjc.org)
  • However, late stent thrombosis is a small but important risk with DESs because it is commonly associated with sudden death or acute MI. (acpjc.org)
  • The clinical diagnosis of stent thrombosis can be defined as "definite" if proven angiographically or pathologically, "probable" if an MI occurs in the distribution of the stented artery, or "possible" if death is unexplained ( 1 ). (acpjc.org)
  • Risk for subacute stent thrombosis is about 1% for both DESs and BMSs, but risk for very late stent thrombosis continues for at least 4 years with DESs at a rate of 2 to 4 events/1000 patients per year (1−3). (acpjc.org)
  • Background First generation drug-eluting stents (DES) were associated with a high incidence of late stent thrombosis (ST), mainly due to delayed healing and re-endothelization by the durable polymer coating. (eur.nl)
  • The frequency of cardiac death and stent thrombosis was low for both Nano and Partner SES (0.8% vs. 0.7%, 0.8% vs. 1.5%, both P=1.00). (eur.nl)
  • However, the antiproliferative properties of DES also delay vascular healing and have been associated with stent malapposition, hypersensitivity reactions and late stent thrombosis. (invasivecardiology.com)
  • Stent thrombosis could result in myocardial infarction or death. (invasivecardiology.com)
  • Late-acquired stent malapposition has been associated with the occurrence of late stent thrombosis following DES implantation.1 As shown in our case, the ISA may have been associated with poor endothelialization of the stent struts and exposure of the stent struts to the blood stream, which provides a nidus for thrombus formation, as shown in this patient. (invasivecardiology.com)
  • Further studies are needed, therefore, to clarify the association between ISA and late stent thrombosis. (invasivecardiology.com)
  • Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. (invasivecardiology.com)
  • LONDON , July 11, 2019 /PRNewswire/ -- Meril's recently CE-approved MeRes100, used for the treatment of de-novo coronary artery lesions, has demonstrated zero scaffold thrombosis and very low Major Adverse Cardiac Event (MACE) rate of 1.87% at three years as shown in MeRes-1 and 1.61% in MeRes-1 Extend at two years. (prnewswire.co.uk)
  • Stent thrombosis is a thrombotic occlusion of a coronary stent. (oncologynurseadvisor.com)
  • Underlying stent: bare-metal stent versus first generation drug-eluting stent versus second-generation drug-eluting stent thrombosis. (oncologynurseadvisor.com)
  • Diagnostic Confirmation: Are You Sure Your Patient Has Stent Thrombosis? (oncologynurseadvisor.com)
  • Definite stent thrombosis: a patient with clinical signs or symptoms of an acute coronary syndrome and angiographic or autopsy evidence of a thrombus 5 mm proximal or distal to the stent. (oncologynurseadvisor.com)
  • Probable stent thrombosis: an unexplained death within 30 days of stent implant or any myocardial infarction with ischemia in the same territory of the stent, but angiography was not performed. (oncologynurseadvisor.com)
  • Possible stent thrombosis: any unexplained death beyond 30 days of stent implant. (oncologynurseadvisor.com)
  • Any patient with prior percutaneous coronary intervention who presents with signs/symptoms consistent with an acute coronary syndrome, especially when there is ischemia in the territory of the prior stent, should be considered for stent thrombosis. (oncologynurseadvisor.com)
  • A consideration which raises the likelihood of stent thrombosis is recent termination of an adenosine diphosphate(ADP) receptor antagonist (i.e., clopidogrel, prasugrel, or ticagrelor) and/or aspirin. (oncologynurseadvisor.com)
  • While stent thrombosis can be a devastating event, fortunately it is a rare problem after percutaneous coronary intervention (PCI). (oncologynurseadvisor.com)
  • First generation drug-eluting stents (paclitaxel-eluting and sirolimus-eluting) have a higher rate of late and especially very late stent thrombosis compared with bare-metal stents. (oncologynurseadvisor.com)
  • In fact, everolimus-eluting and zotarolimus-eluting stents are associated with a lower frequency of total and very late stent thrombosis not only compared with paclitaxel-eluting or sirolimus-eluting stents but also compared with bare-metal stents. (oncologynurseadvisor.com)
  • This is in contrast to stent thrombosis, which presents suddenly and can occur at any time after the procedure. (oncologynurseadvisor.com)
  • Since stent thrombosis patients present with an acute coronary syndrome, they may have signs/symptoms of heart failure or cardiogenic shock. (oncologynurseadvisor.com)
  • however, the patient may also have progression of disease upstream or downstream of the stented segment, which would not be due to stent thrombosis per se. (oncologynurseadvisor.com)
  • Laboratory studies are not necessary to establish the diagnosis of stent thrombosis. (oncologynurseadvisor.com)
  • Suspected stent thrombosis is an emergent condition which needs to be handled like any acute myocardial infarction. (oncologynurseadvisor.com)
  • Explain that data from a worldwide registry of more than 15,000 patients found that those treated with sirolimus-eluting coronary stents had a low one-year incidence of stent thrombosis and major bleeding epidsodes with dual antiplatelet therapy. (medpagetoday.com)
  • Point out that two-thirds of stent thrombosis episodes occurred within 30 days, and the event was particularly uncommon after six months whereas the rate of major bleeding remained linear throughout follow-up. (medpagetoday.com)
  • Analysis of the data, from 56 countries where the stents are approved, revealed that stent thrombosis and major bleeding occurred in just 1% of the more than 15,000 registry patients, according to a report in the March 29 issue of the Journal of the American College of Cardiology . (medpagetoday.com)
  • Mortality and the rates of myocardial infarction and target lesion revascularization were low, although occurrence of stent thrombosis substantially increased the seven-day and one-year mortality risk, noted Philip Urban, MD, of La Tour Hospital in Geneva, Switzerland, and colleagues. (medpagetoday.com)
  • While advanced age and a high Charlson index increased the risk of both stent thrombosis and major bleeding, and stent thrombosis and major bleeding often occurred in the same patient subsets, individual patients who experienced adverse events were either 'bleeders' or 'clotters' and very rarely experienced both adverse events during the first year of follow-up," Urban and co-authors concluded. (medpagetoday.com)
  • Stent thrombosis remains the principal safety concern and late complication associated with sirolimus-eluting and bare-metal stents, the authors noted in the introduction to their findings. (medpagetoday.com)
  • The rate of stent thrombosis has declined with better implantation techniques and stent designs, safer and more effective antithrombotic regimens, and better compliance with antiplatelet therapy. (medpagetoday.com)
  • Moreover, evidence is lacking on the relationship between long-term bleeding complications and stent thrombosis in the general population of patients treated with drug-eluting stents. (medpagetoday.com)
  • Urban and co-authors sought to determine the one-year incidence and consequences of stent thrombosis and major bleeding among patients in the prospective e-SELECT (Multi-Center Post-Market Surveillance) registry of patients who received sirolimus-eluting stents. (medpagetoday.com)
  • In this prospective randomized trial, bare metal stent implantation will be compared with sirolimus-eluting stent implantation for the treatment of chronic total coronary occlusions. (clinicaltrials.gov)
  • 2 D to 12 M, 24 lesions) implantation was investigated histopathologically in necropsied coronary arteries. (ahajournals.org)
  • The objective of the MANIPAL-FLEX study was to evaluate the feasibility, preliminary safety, and efficacy of the Supraflex sirolimus-eluting stent (SES) implantation, in de novo coronary artery disease, using clinical and quantitative coronary angiography (QCA) follow-ups. (hindawi.com)
  • The proprietary, top-quality coating process allows the integrity of coated polymer after excessive stent expansion and a systemic elution of sirolimus in a well -controlled fashion after the stent implantation. (ecvv.com)
  • Our objective was to assess the vascular response secondary to sirolimus drug-eluting stent implantation using different doses and patterns of elution by means of serial intravascular ultrasound (IVUS) analysis. (scielo.br)
  • Objectives This study was designed to compare the clinical and angiographic outcomes of sirolimus-eluting stent (SES) and bare metal stent (BMS) implantation for unprotected left main coronary artery (LMCA) stenosis. (onlinejacc.org)
  • Objectives This study sought to evaluate the long-term arterial response after sirolimus-eluting stent implantation. (onlinejacc.org)
  • Conclusions Between two and four years after sirolimus-eluting stent implantation, peri-stent tissue shrank with a concomitant increase in echogenicity. (onlinejacc.org)
  • These intravascular ultrasound findings suggest that late chronic artery responses may evolve for up to four years after sirolimus-eluting stent implantation. (onlinejacc.org)
  • Several factors are involved in this phenomenon including material and stent platform, target vessel features, stent implantation technique, and implant duration. (ovid.com)
  • METHODS In a prospective randomized multicenter clinical trial, 60 patients with acute coronary syndromes were randomized 1:1 to COMBO or CoCr EES implantation. (uzh.ch)
  • The percentage of uncovered stent struts per stent was somewhat higher after COMBO versus CoCr EES implantation as detected by optical coherence tomography, associated with reduced neointimal thickness. (uzh.ch)
  • Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial. (semanticscholar.org)
  • Eighty-seven patients who had undergone successful stent implantation with 95 DES and post-stenting IVUS were enrolled in this study. (kjim.org)
  • The authors had to cover plaque entirely with SES, so SES implantation usually took longer than the bare stent (BS). (bvsalud.org)
  • Implantation of drug-eluting stents at atherosclerotic ostial lesions of the coronary arteries is currently considered a reasonable treatment strategy, and sirolimus-eluting stents (SESs) have been widely used for intervention in ostial lesions. (kjim.org)
  • Late incomplete stent apposition (ISA) may occur after drug-eluting stent implantation, affecting long-term clinical outcomes. (bvsalud.org)
  • One hundred and thirty-seven patients with coronary artery disease received SES implantation during PCI and had repeat angiography with IVUS examination. (bvsalud.org)
  • The occurrence of late ISA after SES implantation may be related to clinical status, use of long stents , and marked positive vessel remodeling . (bvsalud.org)
  • Drug-eluting stents (DES) are a standard metallic coronary stent with a polymer coating and an antiproliferative drug, which allows drug elution into the coronary wall for weeks to months after stent implantation. (medscape.com)
  • Attached to the stent is a polymer that is embedded with an antiproliferative drug, which allows drug elution into the coronary wall for weeks to months after stent implantation to reduce the local proliferative healing response. (medscape.com)
  • In a 5-year study of outcomes from the j-CYPHER registry which compared sirolimus-eluting stent treatment in 397 patients with ostial right coronary artery (RCA) lesions with 3716 patients with nonostial RCA lesions, researchers concluded that sirolimus-eluting stent implantation for ostial RCA was associated with a higher risk of target legion revascularization than when used in patients with nonostial RCA lesions. (medscape.com)
  • After vascular injury by balloon angioplasty or stent implantation, diverse mechanisms are activated, leading to neointimal hyperplasia. (nature.com)
  • Since the balloon is immediately deflated after maximal inflation during stent implantation and 80% of the expandable wire mesh of the stent was open surface opposing elastic recoil, the process minimized endothelial damage compared to balloon angioplasty alone [ 5 ]. (mdpi.com)
  • METHODS: A total of 54 patients, who underwent elective stent implantation for single de novo native coronary artery lesions, were enrolled: 27 patients treated with the BVS and 27 patients treated with the everolimus-eluting cobalt chromium stent (EES). (biomedsearch.com)
  • Le MQ, Narins CR.Mycotic psuedoaneurysm of the left circumflex coronary artery: a fatal complication following drug-eluting stent implantation. (springer.com)
  • Nakazawa G, Yazdani SK, Finn AV, Vorpahl M, Kolodgie FD, Virmani R. Pathological findings at bifurcation lesions: the impact of flow distribution on atherosclerosis and arterial healing after stent implantation. (springer.com)
  • Clinical and angiographic outcome of elective stent implantation in small coronary vessels: an analysis of the BENESTENT trial. (biomedsearch.com)
  • We examined the influence of vessel size using an intention-to-treat approach in 259 patients who underwent stent implantation and in 257 patients who underwent balloon angioplasty alone in the BENESTENT trial. (biomedsearch.com)
  • Cost effectiveness of stent implantation versus PTCA: the BENESTENT experience. (biomedsearch.com)
  • A fixed amount of sirolimus per unit area is applied to the CYPHER stent, which is designed to release about 80% of the drug within 30 days of implantation. (cmaj.ca)
  • Diabetic patients often present unfavorable coronary anatomy with small and diffusely diseased vessels (1) and exhibit exaggerated neointimal hyperplasia after bare-metal stent (BMS) implantation as compared with nondiabetics (2). (bioportfolio.com)
  • balloon angioplasty') and coronary stent implantation. (portlandpress.com)
  • Stent implantation has become commonplace since the mid-1990s and technology in this area continues to grow. (portlandpress.com)
  • Over 90% of PCI procedures performed in the U.K. today involves the implantation of an intraluminal stent. (portlandpress.com)
  • In patients with coronary artery disease, drug-eluting stents are not more effective in reducing mortality than bare-metal stents up to 4 years after implantation. (acpjc.org)
  • As stent implantation alters local shear stress distribution, stenting near bifurcations is likely to create further blood flow perturbations [ 4 , 5 ]. (royalsocietypublishing.org)
  • We describe here a case report of late stent malapposition following sirolimus-eluting stent implantation observed by angiography, intravascular ultrasound, optical coherence tomography and angioscopy. (invasivecardiology.com)
  • A 39-year-old male underwent stent implantation (Cypher™ 3.5-33 mm, Cordis Corp., Miami Lakes, Florida) for acute coronary syndrome in a proximal left anterior descending (LAD) artery lesion. (invasivecardiology.com)
  • This case demonstrates late-acquired stent malapposition following sirolimus-eluting stent implantation for the treatment of acute coronary syndrome. (invasivecardiology.com)
  • In 2005, data were also presented showing how the CYPHER® Stent performed in trials examining complex lesions. (eurekalert.org)
  • The coronary disease in these patients was complex because of the frequent presence of diabetes (in 26 percent of patients), the high percentage of patients with longer lesions (mean, 14.4 mm), and small vessels (mean, 2.80 mm). (nih.gov)
  • Comparison of sirolimus eluting stent with bioresorbable polymer to everolimus eluting stent with permanent polymer in bifurcation lesions: Results from CENTURY II trial. (terumo-europe.com)
  • These patients were at high risk for developing ISR, with 17 lesions in native coronary arteries (9 de novo and 8 ISR), without angina or documented ischemia. (scielo.br)
  • 1162 patients (1619 lesions) were assigned to receive the zotarolimus-eluting stent, and 1170 patients (1611 lesions) to receive the sirolimus-eluting stent. (nih.gov)
  • 67 patients (72 lesions) had stent failure, and six patients were lost to follow-up. (nih.gov)
  • The main objective of this study is to demonstrate the superiority or non-inferiority of the sirolimus-eluting Bx VELOCITY® stent compared to intravascular brachytherapy in patients with in-stent restenotic native coronary artery lesions. (clinicaltrials.gov)
  • In the United States, the CYPHER(R) Stent is indicated for previously untreated lesions that are less than 30 mm in length with a reference vessel diameter ranging from more than 2.50 mm to less than 3.50 mm. (bio-medicine.org)
  • Consecutive patients with a history of previous CABG and de novo lesions (n=47) treated exclusively with SES, were compared to 66 patients who received bare stents in the 6-month period just before SES introduction. (nih.gov)
  • Coronary bifurcations represent a challenging lesions subset and account for up to 15% of all current PCI. (dovepress.com)
  • Conclusions The third-generation VES demonstrated excellent acute results in the treatment of de novo coronary lesions. (onlinejacc.org)
  • Objectives The aim of this analysis was to assess the 7-year long-term safety and effectiveness of a randomized comparison of percutaneous coronary intervention (PCI) with sirolimus-eluting stents (SES) versus minimally invasive direct coronary artery bypass (MIDCAB) surgery for the treatment of isolated proximal left anterior descending lesions. (onlinejacc.org)
  • OBJECTIVES We aimed to compare the long-term clinical outcomes of patients treated with sirolimus-eluting stents (SES) or paclitaxel-eluting stents (PES) for coronary bifurcation lesions. (semanticscholar.org)
  • METHODS Patients who received percutaneous coronary intervention for non-left main bifurcation lesions were enrolled from 16 centers in Korea between January 2004 and June 2006. (semanticscholar.org)
  • Comparison of the first- and second-generation limus-eluting stents for bifurcation lesions from a Korean multicenter registry. (semanticscholar.org)
  • The impact of side branch predilatation on procedural and long-term clinical outcomes in coronary bifurcation lesions treated by the provisional approach. (semanticscholar.org)
  • Three-year follow-up of patients with bifurcation lesions treated with sirolimus- or everolimus-eluting stents: SEAside and CORpal cooperative study. (semanticscholar.org)
  • Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III: Sirolimus vs. Everolimus-eluting Stent. (springer.com)
  • Methods and Results - This multicenter trial randomly assigned 238 patients to revascularization of single, de novo, native coronary artery lesions with sirolimus-eluting versus conventional bare-metal stents. (elsevier.com)
  • Recent intravascular ultrasound (IVUS) studies of sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) have demonstrated a significant reduction in neointimal hyperplasia (NIH) based on simple coronary lesions. (kjim.org)
  • In this study, we evaluated the efficacy of SES and PES using IVUS in complex coronary lesions. (kjim.org)
  • Eighty-seven patients in whom 95 drug-eluting stents (66 SES and 29 PES) were implanted in complex coronary lesions were enrolled in this study. (kjim.org)
  • Although SES showed significantly greater suppression of NIH at follow-up, both stents were highly effective at inhibiting NIH in complex coronary lesions. (kjim.org)
  • However, these studies mostly focused on simple coronary lesions, although DES tend to be used in patients with more complex lesions, which are associated with higher rates of MACE. (kjim.org)
  • The SES group consisted of 59 patients with 62 native coronary lesions (66 DES), while the PES group consisted of 28 patients with 29 native coronary lesions (29 DES). (kjim.org)
  • Recently, percutaneous coronary intervention has been increasingly applied to unprotected LMCA lesions. (naver.com)
  • The SES were usually implanted at middle part of the left anterior descending artery (MLAD) (11 lesions), proximal part of the left anterior descending artery (PLAD) (8 lesions), middle part of the right coronary artery (MRCA) (8 lesions) and middle part of the left circumflex artery (MLCX) (6 lesions). (bvsalud.org)
  • These stents are FDA approved for single de novo coronary lesions of limited length within specific diameter size ranges. (medscape.com)
  • [ 1 ] which compared the sirolimus-eluting CYPHER stent with its noncoated counterpart, the BX velocity stent, in 238 patients with de novo lesions less than 18 mm in length in native coronary arteries 2.5-3.5 mm in diameter. (medscape.com)
  • The SIRIUS trial, which included 1058 patients with workhorse lesions who were randomly assigned to either sirolimus-eluting stents or BMS, demonstrated the long-term efficacy and safety of sirolimus-eluting stents. (medscape.com)
  • A total of 183 patients with de novo lesions in native coronary arteries were randomized 2:1 to Combo (n = 124) or Taxus Liberté (n = 59). (nih.gov)
  • Importantly, patients in the randomised studies mentioned above have generally had relatively simple coronary lesions, whereas, in the "real world", DES are frequently used for more complex coronary lesions that have not necessarily been evaluated by these trials. (mja.com.au)
  • Despite the extensive clinical use of DESs to maintain vascular patency, not all coronary lesions are amenable to DES placement ( 2 ). (pnas.org)
  • The optimal treatment for coronary bifurcation lesions is still the subject of debate. (springer.com)
  • With the advent of bare-metal stents, the first controversies arose as to whether one or several stents should be used to treat these lesions. (springer.com)
  • Asakura T, Karino T. Flow patterns and spatial distribution of atherosclerotic lesions in human coronary arteries. (springer.com)
  • Intravascular ultrasonic analysis of atherosclerotic vessel remodeling and plaque distribution of stenotic left anterior descending coronary arterial bifurcation lesions upstream and downstream of the side branch. (springer.com)
  • ultrasound study of the prevalence of plaque at the carina in lesions that affect the coronary bifurcation. (springer.com)
  • Treatment of arterial bifurcation lesions using drug-eluting stents (DES) is now common clinical practice and yet the mechanisms governing drug distribution in these complex morphologies are incompletely understood. (plos.org)
  • This study sought to assess the safety and efficacy of the Nano polymer-free sirolimus-eluting stent (SES) in the treatment of patients with de novo coronary artery lesions. (eur.nl)
  • Methods The Nano trial is the first randomized trial designed to compare the safety and efficacy of the Nano polymer-free SES and Partner durable-polymer SES (Lepu Medical Technology, Beijing, China) in the treatment of patients with de novo native coronary lesions. (eur.nl)
  • Conclusions In this multicenter randomized Nano trial, the Nano polymer-free SES showed similar safety and efficacy compared with the Partner SES in the treatment of patients with de novo coronary artery lesions. (eur.nl)
  • The patients received a total of 23,492 sirolimus-eluting stents during interventions to treat 19,988 lesions. (medpagetoday.com)
  • The company will also stop the manufacture of CYPHER® and CYPHER SELECT® Plus Sirolimus-Eluting Coronary Stents by the end of 2011. (mdtmag.com)
  • In this prospective, randomized, single-blind trial we enrolled 200 patients with chronic total occlusions: 100 were randomly assigned to receive bare metal BxVelocity™ stents, and 100 to receive sirolimus-eluting Cypher™ stents. (clinicaltrials.gov)
  • The late loss results in the main vessel and adjoining side branch also favored those patients treated with the CYPHER® Stent. (eurekalert.org)
  • This study was one of many clinical successes in 2005 for the CYPHER Stent. (eurekalert.org)
  • During the year, the CYPHER Stent experienced exponential growth worldwide, driven by numerous positive results from randomized controlled trials as well as meta-analyses of these trials presented at leading medical meetings and published in peer-reviewed journals including the New England Journal of Medicine (NEJM), Journal of the American Medical Association (JAMA), Circulation and the Journal of the American College of Cardiology (JACC). (eurekalert.org)
  • Clinical data results helped re-establish the CYPHER® Stent as the leading drug-eluting stent globally. (eurekalert.org)
  • This year brought an impressive volume of positive new data on the CYPHER® Stent," said Dennis Donohoe, MD, Worldwide Vice President, Clinical Research and Regulatory Affairs, Cordis Corporation. (eurekalert.org)
  • Overwhelmingly, these data have confirmed the unsurpassed long-term efficacy and the trusted safety profile of the CYPHER® Stent and have been instrumental in establishing Cordis Corporation as the worldwide market leader in drug-eluting stents. (eurekalert.org)
  • The global REALITY study presented in March documented that the CYPHER® Stent was associated with significantly less late loss compared to the Taxus Stent. (eurekalert.org)
  • In addition, when focused on small vessel diameters, the CYPHER Stent was associated with fewer blood clots at the stent site (stent thromboses) compared to the Taxus stent. (eurekalert.org)
  • Other trials presented this year also had results favoring the CYPHER Stent compared to the Taxus Stent, including: ISAR-DESIRE and an independent meta-analysis both published in JAMA, and ISAR-DIABETES published in NEJM. (eurekalert.org)
  • It is reassuring to see data that documents the CYPHER® Stent performs reliably over the long haul, and does so with a strong safety profile. (eurekalert.org)
  • Of note was the PRISON II study, which looked at patients with chronic total occlusions and an analysis of four trials, including the SIRIUS, E-SIRIUS, C-SIRIUS and DIRECT trials, that provided information about use of CYPHER in long coronary blockages when those blockages were treated with multiple, overlapping or non-overlapping CYPHER® Stents, rather than with a bare metal stent. (eurekalert.org)
  • The SISR trial, which featured a randomized trial design, compared CYPHER Stent to radiation within a vessel (brachytherapy). (eurekalert.org)
  • Finally, a cost-effectiveness analysis of the ARTS I and II trials demonstrated that treatment with the CYPHER® Stent offers potential cost-savings over bypass surgery, a finding that supports the use of drug-eluting stents in treating certain complex patient cases that would have otherwise been directed to surgery. (eurekalert.org)
  • The company intends to close two manufacturing facilities: Cashel, Ireland , where the NEVO™ Stent was to be produced, and San German, Puerto Rico , the manufacturing site for the CYPHER® Stent products. (fiercepharma.com)
  • Unlicensed competition from products that infringe Cordis patents, both owned and licensed, has eroded CYPHER® Stent pricing, sales and market share, and has dampened the prospects for NEVO™ Stent commercialization. (fiercepharma.com)
  • Long-term, follow-up data presented today suggest that patients who received the CYPHER Sirolimus-eluting Coronary Stent for blockage of a bare metal stent were significantly less likely to need another procedure (target lesion revascularization or TLR) at three years compared to patients who received brachytherapy. (webwire.com)
  • These data continue to favor the CYPHER Stent compared to radiation therapy in these patients with complex coronary artery disease, said David R. Holmes Jr., M.D., Principal Investigator and Professor of Medicine, The Mayo Clinic College of Medicine, Rochester, MN. (webwire.com)
  • At three years, 81 percent of patients who received the CYPHER Stent were free from a TLR compared to 71.6 percent of patients receiving brachytherapy (p=0.018). (webwire.com)
  • For target vessel revascularization, the survival free rates were 78.2 percent for the CYPHER Stent and 68.8 percent for the brachytherapy arm (p=0.022). (webwire.com)
  • Rates of MACE were 75.5 percent for the CYPHER Stent and 70.5 percent for brachytherapy (p=0.186). (webwire.com)
  • ACROSS-Cypher® is a prospective, multi-center, open label, single arm study of the Cypher® sirolimus eluting coronary stent in native total coronary occlusion revascularization. (bioportfolio.com)
  • The Impact of Stent Deployment Techniques on Clinical Outcomes of Patient Treated With the CYPHER® Stent (S.T.L.L.R. (bioportfolio.com)
  • 1500 eligible patients will be treated with the commercially available CYPHER® sirolimus-eluting Bx Velocity™ stent. (bioportfolio.com)
  • The main objective of this study is to assess the safety and effectiveness of the Sirolimus eluting Cypher Select(TM) stent in reducing angiographic in-stent late loss in de novo native co. (bioportfolio.com)
  • The Cordimax stent has proved non-inferior to the Cypher Select durable polymer sirolimus-eluting stent for the primary endpoint of angiographic in-stent late luminal loss and in-stent mean diameter s. (bioportfolio.com)
  • MIAMI LAKES, Fla., June 4, 2007 /PRNewswire via COMTEX News Network/ -- An analysis of data from the Western Denmark Heart Registry found that patients who received the CYPHER(R) Sirolimus-eluting Coronary Stent to open a clogged artery were less likely to need another procedure at that same lesion site (a clinical event called target lesion revascularization or TLR) than patients who received a Taxus Stent. (bio-medicine.org)
  • The authors of the analysis sought to identify risk factors for symptom- driven TLR when patients were treated with the CYPHER(R) Stent or the Taxus Stent in a real-world scenario. (bio-medicine.org)
  • The major new finding of this study was that the use of the Taxus Stent was an independent predictor of TLR for a real-world population of patients treated with the CYPHER(R) Stent and the Taxus Stent," said Michael Maeng, M.D., Principal Investigator, from Aarhus University Hospital, Denmark. (bio-medicine.org)
  • These registry findings provide additional assurance to the interventional cardiology community regarding the efficacy of the CYPHER(R) Stent to prevent the need for repeat revascularizations in a real-world clinical setting," said David E. Kandzari, M.D., F.A.C.C., F.S.C.A.I., Chief Medical Officer, Cordis Cardiology Division of Cordis Corporation. (bio-medicine.org)
  • The CYPHER(R) Stent has been chosen by cardiologists worldwide to treat approximately three million patients with coronary artery disease. (bio-medicine.org)
  • The safety and efficacy of the device is supported by a robust clinical trial program that includes more than 70 studies that examine the performance of the CYPHER(R) Stent in a broad range of patients. (bio-medicine.org)
  • Developed and manufactured by Cordis Corporation, the CYPHER(R) Stent is currently available in more than 80 countries and has the broadest clinical experience and longest-term clinical follow-up of any drug-eluting stent. (bio-medicine.org)
  • The next version of sirolimus-eluting stent, the CYPHER(R) SELECT(TM) Sirolimus- eluting Coronary Stent, was launched in Europe, Asia Pacific, Latin America and Canada in 2003. (bio-medicine.org)
  • The CYPHER(R) SELECT(TM) Plus Stent, the third version of a sirolimus-eluting coronary stent, received CE Mark in 2006 and is currently available in many markets outside the United States. (bio-medicine.org)
  • In the 10 ± 1 month followup, Cypher ® , Redox ® and VESTAsync TM stents showed a late luminal loss of 0.16 ± 0.36 mm, 0.24 ± 0.33 mm, 0.37 ± 0.24 mm, respectively (P = 0.19). (scielo.br)
  • Serial IVUS analysis showed Cypher ® and Redox ® stents with mild positive vascular remodeling translated by non-significant vessel volume increase of 0.1 ± 1.6 mm 3 /mm and 0.5 ± 0.6 mm 3 /mm, respectively. (scielo.br)
  • In the current study, based on data from the Western Denmark Heart Registry (WDHR), we used the sirolimus-eluting Cypher™ stent (SES) as the comparator stent. (biomedcentral.com)
  • He had coronary risk factors including hypertension and an episode of treatment with percutaneous coronary intervention (PCI) with a 3.5 × 13 mm SES (Cypher, Cordis, Johnson & Johnson, Miami Lakes, FL, USA) at the ostium of the LM 2 years earlier. (kjim.org)
  • In a press release (see below) the company announced that it was discontinuing development of the Nevo sirolimus-eluting stent and that it would also stop making its original Cypher stent by the end of the year. (cardiobrief.org)
  • A sirolimus-eluting coronary stent was marketed by Cordis, a division of Johnson & Johnson, under the tradename Cypher. (wikipedia.org)
  • This is for both the Taxus and Cypher stents. (healingwell.com)
  • stents, the Cypher, are coated (drug eluting) with Sirolimus. (healingwell.com)
  • I have 2 Taxus stents and 2 Cypher stents. (healingwell.com)
  • A subgroup analysis of diabetic patient data from a two-year randomized controlled trial comparing the CYPHER Sirolimus-eluting Coronary Stent to the Taxus Stent showed no statistically significant differences in safety outcomes between the two drug-eluting stents. (webwire.com)
  • The authors of the analysis, presented today at the European Society of Cardiology Congress 2007 (ESC Congress 2007), also reported that in the CYPHER Stent arm there were numerically lower rates of cardiac mortality, blood clots and heart attack rates than in the Taxus Stent arm, although these differences did not reach statistical significance. (webwire.com)
  • In this analysis of head-to-head randomized controlled trial data, both drug-eluting stents yielded similar safety outcomes and the CYPHER Stent presented safety rates in some areas that were numerically lower, Giulio Guagliumi, M.D., from the Ospedale Riuniti Di Bergamo in Bergamo, Italy, who presented the results on behalf of the REALITY Trial investigators. (webwire.com)
  • The cardiac death rates were 1.6 percent for the CYPHER Stent and 4.7 percent for the Taxus Stent (p=0.14). (webwire.com)
  • The rate of Q-wave myocardial infarction (heart attacks that involve the full thickness of the heart wall) was 0.0 percent for the CYPHER Stent and 1.6 percent for the Taxus Stent (p=0.25). (webwire.com)
  • In addition, the rates of non-Q wave myocardial infarctions (heart attacks that do not involve the full thickness of the heart wall) were 4.8 percent for the CYPHER Stent and 5.2 percent for the Taxus Stent (p=1.00). (webwire.com)
  • None of these numerical differences in favor of the CYPHER Stent reached statistical significance. (webwire.com)
  • The MACE rate for the CYPHER Stent was 15.5 percent while the MACE rate for the Taxus Stent was 14.1 percent (p=0.77). (webwire.com)
  • This analysis provides additional and relevant information to doctors regarding the long-term efficacy and safety outcomes in diabetic patients treated with either the CYPHER Stent or the Taxus Stent. (webwire.com)
  • These patients were randomly selected to receive either the CYPHER Stent or the Taxus Stent. (webwire.com)
  • In the end, the CYPHER Stent was used in 684 patients and 970 artery blockages, while the Taxus Stent was used in 669 patients and 941 artery blockages. (webwire.com)
  • The CYPHER stent, a metal device that is coated with sirolimus, was approved in April 2003 by the US Food and Drug Administration (FDA) for use in angioplasty procedures. (cmaj.ca)
  • Furthermore, it should be noted that in 1 major study that demonstrated the benefits of the CYPHER stent 7 the device was investigated in a limited clinical application. (cmaj.ca)
  • Cypher releases sirolimus, an immune-suppressing agent, and Boston Scientific?s Taxus releases paclitaxel, an antineoplastic agent that inhibits cell mitosis. (pharmacytimes.com)
  • An abluminal biodegradable polymer sirolimus-eluting stent versus a durable polymer everolimus-eluting stent in patients undergoing coronary revascularization: 3-year clinical outcomes of a randomized non-inferiority trial. (bioportfolio.com)
  • The efficacy of first-generation drug-eluting stents (DES) in reducing in-stent neointimal proliferation and therefore the need for repeat lesion revascularization is irrefutable ( 1,2 ). (onlinejacc.org)
  • Background: Diabetes mellitus is one of the major predictors for target lesion revascularization even in drug-eluting stent era. (octnews.org)
  • Coronary revascularization in diabetic patients: a systematic review and Bayesian network meta-analysis. (semanticscholar.org)
  • Twenty-seven (67.5%) of the patients had complete revascularization by percutaneous coronary intervention (PCI) and only 16 of 27 patients (59.3%) who had complete revascularization with SES. (bvsalud.org)
  • [ 5 , 6 ] In each of these trials, the TAXUS stent resulted in lower target vessel revascularization rates when compared to bare-metal stents, but there was greater lumen loss than had been seen with the sirolimus-eluting stent in the RAVEL trial. (medscape.com)
  • Eligibility criteria for selecting studies A strategy of initial medical treatment compared with revascularisation by coronary artery bypass grafting or Food and Drug Administration approved techniques for percutaneous revascularization: balloon angioplasty, bare metal stent, early generation paclitaxel eluting stent, sirolimus eluting stent, and zotarolimus eluting (Endeavor) stent, and new generation everolimus eluting stent, and zotarolimus eluting (Resolute) stent among patients with stable coronary artery disease. (bmj.com)
  • The development of stents to treat CAD was a significant innovation, facilitating effective percutaneous coronary revascularization. (mdpi.com)
  • Reason for posting: The use of coronary stents has improved the results of percutaneous coronary revascularization procedures. (cmaj.ca)
  • Coronary revascularization for coronary artery disease dates to the introduction of coronary bypass surgery by Favaloro in 1967 and coronary angioplasty by Gruentzig in 1977 and first published in 196. (bioportfolio.com)
  • Although the main strategy for revascularization is by coronary artery bypass graf. (bioportfolio.com)
  • Attempts to ameliorate this proliferative response involve the use coronary stents, which have significantly improved both short-term and long-term outcome following interventional coronary revascularization procedures. (aspetjournals.org)
  • Treatment of ACSs is done initially with pharmacological agents such as aspirin and statins, but when medical therapy fails to control symptoms, revascularization by either CABG (coronary artery bypass grafting) or PCI is indicated. (portlandpress.com)
  • Whether sirolimus-eluting stents are superior to bare metal stents in CTO is unknown. (clinicaltrials.gov)
  • Several studies have demonstrated the safety and feasibility of unprotected left main coronary artery (LMCA) intervention using bare metal stents (BMS) ( 1-8 ). (onlinejacc.org)
  • Sirolimus-eluting stents reduce long-term mortality compared with bare metal stents in ST-segment elevation myocardial infarction: a meta-analysis of randomized controlled trials. (semanticscholar.org)
  • Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. (acpjc.org)
  • In patients with coronary artery disease (CAD), how do sirolimus-eluting stents (SESs) compare with bare-metal stents (BMSs) for long-term survival? (acpjc.org)
  • Initially, drug-eluting stents (DES) were compared to bare-metal stents (BMS) for efficacy. (medscape.com)
  • The paclitaxel-eluting stent was initially compared to bare-metal stents in sequentially numbered TAXUS trials. (medscape.com)
  • paclitaxel: 0.44, 0.35 to 0.54), and bare metal stents (0.69, 0.59 to 0.81) compared with medical treatment. (bmj.com)
  • 1 Two basic stent types are used: bare-metal stents (BMS) that cost about $800 each, and drug-eluting stents (DES) that cost about $3300 each. (mja.com.au)
  • In some cases, only bare metal stents (BMSs) may be applied, which lack the benefit of antirestenotic therapy and instead stimulate neointimal smooth muscle cell (SMC) proliferation ( 7 , 8 ). (pnas.org)
  • Recently, controversy surrounding the advantages and disadvantages of drug-eluting stents (DES), compared with bare-metal stents (BMS), in ACS has filled the editorial pages of clinical journals. (pharmacytimes.com)
  • Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. (acpjc.org)
  • In patients with coronary artery disease who are receiving percutaneous coronary intervention and stent placement, are drug-eluting stents (DESs) more effective than bare-metal stents (BMSs) in reducing mortality? (acpjc.org)
  • DES have also been shown to significantly reduce neointimal hyperplasia as compared to bare-metal stents. (invasivecardiology.com)
  • Sirolimus eluting stents versus bare metal stents in patients with ST- segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome. (invasivecardiology.com)
  • With first generation drug-eluting stents, early events occur at the same low frequency as bare-metal stents. (oncologynurseadvisor.com)
  • One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in diabetic patients: Insight from the ULISSE registry (ULtimaster Italian multicenter all comerS Stent rEgistry). (bioportfolio.com)
  • The ULISSE registry evaluated the real-world performance of the Ultimaster® biodegradable polymer sirolimus-eluting stent (BP-SES) in a multicenter-independent cohort of patients undergoing percutane. (bioportfolio.com)
  • The Firehawk Stent: A Review of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent. (bioportfolio.com)
  • This DES uses a biodegradable polymer coating on the stainless steel stent platform. (ecvv.com)
  • 2-year outcome after biodegradable polymer sirolimus- and. (au.dk)
  • Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial. (unil.ch)
  • Biodegradable polymer stents might improve long-term outcomes, but studies with early biodegradable polymer stents that had thick stainless steel struts (120 µm) showed equivocal results. (crf.org)
  • However, very thin-strut (60-81µm) biodegradable polymer stents that have flexible designs and thin, refined coatings are now available. (crf.org)
  • BIO-RESORT (TWENTE III) was a large-scale, investigator-initiated, assessor and patient-blinded, multicenter, three-arm trial that compared the safety and efficacy of two novel, very thin-strut biodegradable polymer stents to an established durable polymer stent (Resolute Integrity). (crf.org)
  • Both biodegradable polymer stents have very thin struts but differ in the type, amount, distribution and degradation speed of their respective coating. (crf.org)
  • The Synergy everolimus-eluting platinum chromium stent is the first and only biodegradable polymer drug-eluting stent approved by the FDA for clinical use in the United States and this was its first randomized assessment in an all-comers population. (crf.org)
  • The Orsirio biodegradable polymer sirolimus-eluting cobalt chromium stent has been used clinically outside the United States. (crf.org)
  • Patients were randomly assigned (1:1:1) to treatment with the very thin-strut biodegradable polymer everolimus-eluting or sirolimus-eluting stents or the durable polymer zotarolimus-eluting stent at four sites in the Netherlands. (crf.org)
  • The one-year results of BIO-RESORT show that treatment with two very thin-strut biodegradable polymer stents and the thin strut durable polymer zotarolimus-eluting stent was similarly efficacious and safe with excellent one-year clinical outcomes in a complex population of all-comers," said Dr. von Birgelen. (crf.org)
  • The absence of a loss of one-year safety and efficacy with the use of these biodegradable polymer-coated stents is a prerequisite before assessing their potential longer-term benefits. (crf.org)
  • CORACTO CORONARY STENT DELIVERY SYSTEM - Drug Eluting Stent with Sirolimus and a biodegradable polymer. (internations.org)
  • XPLOSION+™ Eluting Coronary Stent system is the latest in the second generation of drug eluting stents, an ultimate combination of three outstanding elements: a clinically proven drug - Sirolimus, a modified Cobalt Chromium stent platform, and an excellent bioabsorbable drug carrier. (com.vn)
  • The purpose of this study is the assessment of the performance of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the treatment of the specific setting of pat. (bioportfolio.com)
  • Chronic total occlusion of the left main coronary artery (LMCA) is rare. (naver.com)
  • We describe a patient who experienced migration of a SES without fracture from the ostium of the left main coronary artery (LM) to the right deep femoral artery (RDFA). (kjim.org)
  • Long-Term Clinical Outcomes of Sirolimus- Versus Paclitaxel-Eluting Stents for Patients With Unprotected Left Main Coronary Artery Disease. (elsevier.com)
  • Dive into the research topics of 'Long-Term Clinical Outcomes of Sirolimus- Versus Paclitaxel-Eluting Stents for Patients With Unprotected Left Main Coronary Artery Disease. (elsevier.com)
  • Real-life characteristics and outcomes of patients who undergo percutaneous coronary intervention versus coronary artery bypass grafting for left main coronary artery disease: data from the prospective Multi-vessel Coronary Artery Disease (MULTICAD) Israeli Registry. (bioportfolio.com)
  • Left main coronary artery involvement in patients with multivessel coronary artery disease provides a poor prognosis. (bioportfolio.com)
  • Clinical usefulness of the angle between left main coronary artery and left anterior descending coronary artery for the evaluation of obstructive coronary artery disease. (bioportfolio.com)
  • Comparison of Long-Term Outcome After Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Unprotected Left Main Coronary Artery Disease (from the CREDO-Kyoto PCI/CABG Registry Cohort-2). (nii.ac.jp)
  • Secondary endpoints were a composite of major adverse cardiac events, target vessel failure, in-stent and in-segment minimal lumen diameter, percentage diameter stenosis, and late luminal loss at six months follow-up. (clinicaltrials.gov)
  • Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. (nih.gov)
  • Post-procedure and six-month in-stent and in-lesion percent diameter stenosis (%DS) and late loss at 6 months post-procedure (by QCA) - [analysis at 6 months chosen so that results from the GAMMA Trial can be used]. (clinicaltrials.gov)
  • With the introduction of the drug-eluting stent (DES), re-stenosis rates have been reduced. (bmj.com)
  • It is still not clear yet which is the better strategy between the provisional approach and stenting both branches when dealing with a bifurcation lesion which has a stenosis in the SB suitable for stenting. (dovepress.com)
  • Established treatment options in isolated severe stenosis of the proximal LAD comprise bypass grafting by minimally invasive direct coronary artery bypass (MIDCAB) surgery and percutaneous coronary intervention (PCI) either with bare-metal (BMS) or drug-eluting stents (DES) (3-5) . (onlinejacc.org)
  • At that time, coronary angiography (CAG) revealed an 80% stenosis at the ostium of the LM ( Fig. 1A ), and the minimal luminal area was 4.2 mm 2 on intravascular ultrasound (IVUS) ( Fig. 1B ). (kjim.org)
  • 1 , 2 , 3 However, a persistent problem with stents is the subsequent development of in-stent stenosis. (cmaj.ca)
  • e.g. stent/vessel size mismatch, bifurcation angles, diameter ratios and stenosis, which have not been previously considered. (royalsocietypublishing.org)
  • The ability to achieve a sustained clinical benefit in tough-to-treat patients is a key consideration when choosing a drug-eluting stent," said David R. Holmes, Jr., MD, Professor of Medicine, Mayo Clinic College of Medicine, Rochester, MN. (eurekalert.org)
  • More recently, sirolimus has been used to prevent ISR with a coated stent design with good clinical and angiographic results (11). (scielo.br)
  • A number of clinical studies have tested oral sirolimus to prevent or to treat ISR. (scielo.br)
  • Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled s. (nih.gov)
  • We compared the efficacy and safety of the zotarolimus-eluting stent versus the sirolimus-eluting stent in patients with coronary artery disease who were receiving routine clinical care with no direct follow-up. (nih.gov)
  • The sirolimus-eluting stent is superior to the zotarolimus-eluting stent for patients receiving routine clinical care. (nih.gov)
  • There were no significant differences between the groups (SES and bare stent) with respect to baseline clinical or lesion characteristics. (nih.gov)
  • The bioengineered COMBO Dual Therapy Stent combines CD34+ cell-capturing technology with abluminal sirolimus release, but more data from clinical studies evaluating the vascular response are needed. (uzh.ch)
  • CONCLUSIONS The present multicenter, prospective clinical study for the first time compared the vascular response of the bioengineered COMBO Dual Therapy Stent with a CoCr EES in patients early after acute coronary syndrome by using intracoronary optical coherence tomographic analysis. (uzh.ch)
  • In this preliminary analysis, we present the 4-month clinical, angiographic, and ultrasonographic results of the first 15 patients treated with the novel Vestasync nonpolymer-based sirolimus-eluting stent. (onlinejacc.org)
  • Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis. (semanticscholar.org)
  • It was found that the selective use of one SES combined with one BMS in patients undergoing percutaneous coronary intervention that requires more than one stent is safe, feasible, and associated with favorable procedural, 30-day, and 6-month clinical outcomes when compared to the exclusive use of SESs. (elsevier.com)
  • Clinical experience of sirolimus-eluting stents in patients with coronary artery disease at Bangkok Heart Institute. (bvsalud.org)
  • From the present study, the authors reported clinical experience of SES in 40 consecutive patients with coronary artery disease (CAD) between 25th June and 11th October, 2002. (bvsalud.org)
  • This study aimed to evaluate the impact of clinical presentations of coronary artery disease on late ISA after percutaneous coronary intervention (PCI) with sirolimus -eluting stents (SES) by means of three-dimensional volumetric intravascular ultrasound (IVUS) analyses. (bvsalud.org)
  • Clinical diagnosis of acute coronary syndrome (ACS) and use of long stents were more common in patients with than in those without late ISA. (bvsalud.org)
  • The purpose of this study was to compare clinical outcomes of the EES with the first-generation drug-eluting stent (DES) in CTO intervention and to investigate the predictors of clinical outcome. (elsevier.com)
  • The Biolimus A9-coated BioFreedom™ stent: from clinical efficacy to real-world evidence. (medscape.com)
  • In 2009, the FDA notified healthcare professionals that a clinical trial conducted by Wyeth showed an increased mortality in stable liver transplant patients after switching from a calcineurin inhibitor-based immunosuppressive regimen to sirolimus. (wikipedia.org)
  • The safety and efficacy of sirolimus treatment of LAM were investigated in clinical trials that compared sirolimus treatment with a placebo group in 89 patients for 12 months. (wikipedia.org)
  • Initial clinical trials of these drug-eluting stents have been completed and other trials are underway. (cmaj.ca)
  • The objective of this study is to evaluate the safety and long-term effectiveness of coronary stenting with the everolimus-eluting stent (EES) and to determine clinical device and procedur. (bioportfolio.com)
  • The objective of this study is to evaluate the long-term efficacy and safety of coronary stenting with the various types of drug-eluting stents (DES) and to determine clinical device and p. (bioportfolio.com)
  • WASHINGTON - October 30, 2016 - Results of a large-scale, multicenter study found that treatment with two thin-strut drug-eluting stents were both non-inferior to a durable polymer drug-eluting stent and showed favorable clinical outcomes at one year in treating an all-comers population with a high proportion of patients with acute coronary syndromes. (crf.org)
  • In patients with coronary artery disease treated with durable polymer-coated drug-eluting stents, the life-long presence of the polymer may delay arterial healing and even cause adverse clinical events," said Clemens von Birgelen, MD, PhD, Professor of Medicine at Thoraxcentrum Twente in Enschede, Netherlands. (crf.org)
  • These findings highlight the effects of major biomechanical factors in MB stenting on endothelial WSS, WSSG, OSI and suggests potential mechanisms for the potentially higher adverse clinical events associated with bifurcation stenting. (royalsocietypublishing.org)
  • Stenting at bifurcations is associated with worse clinical outcome than stenting of single vessels [ 3 ]. (royalsocietypublishing.org)
  • Although MB stenting is the current default treatment approach for bifurcations, it may be associated with higher clinical events such as myocardial infarction for certain bifurcation anatomy (diameter ratio, angle, etc.) [ 6 - 8 ]. (royalsocietypublishing.org)
  • Despite the clinical significance, there have been far fewer CFD studies of bifurcation stenting than single vessel stents [ 11 , 12 ]. (royalsocietypublishing.org)
  • We are aiming to continue further developing the clinical evidence of this next generation technology against a drug-eluting stent in a randomised setting in due course. (prnewswire.co.uk)
  • Three-year clinical and two-year multimodality imaging outcomes of a thin-strut sirolimus-eluting bioresorbable vascular scaffold: MeRes-1 trial. (prnewswire.co.uk)
  • 2. Abizaid A. MeRes-1 Extend study: Imaging and two-year clinical outcomes of thin strut sirolimus-eluting bioresorbable vascular scaffold in patients with coronary artery disease. (prnewswire.co.uk)
  • However, compared with balloon angioplasty (BA) and restricted stenting, routine coronary stenting is not associated with reductions in mortality, MI, or coronary artery bypass surgery ( 1 ). (acpjc.org)
  • Deployment of a stent overcomes some limitations of balloon angioplasty alone, but provides an acute stimulus for thrombus formation and promotes neointimal hyperplasia. (mdpi.com)
  • Depending on the severity of the disease, the main interventional options for revascularisation include angioplasty, stent deployment and in severe, diffuse occlusions (more than 70%), bypass graft surgery [ 3 ]. (mdpi.com)
  • Narrowed coronary arteries were originally treated percutaneously with balloon angioplasty alone [ 4 ]. (mdpi.com)
  • Stents were initially evaluated in a preclinical study relative to angioplasty alone, in canine coronaries to assess efficacy prior to human trials [ 5 , 7 ]. (mdpi.com)
  • P ercutaneous coronary intervention (angioplasty) using stents is a common procedure in Australia, with over 30 000 cases performed each year. (mja.com.au)
  • Logistic regression indicated that decreasing vessel size (as a continous variable) was associated with an increasing risk of a cardiac event for both the stent and balloon angioplasty populations. (biomedsearch.com)
  • previously called angioplasty, percutaneous transluminal coronary, or balloon angioplasty). (pharmacytimes.com)
  • Therefore, stent placement has replaced balloon angioplasty as the treatment of choice. (pharmacytimes.com)
  • The frequency of neointimal hyperplasia within the stent was also decreased in the group that received sirolimus-eluting stents, as assessed by both angiography and intravascular ultrasonography. (nih.gov)
  • 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. (semanticscholar.org)
  • In addition, in the evaluation of procedural results, two-dimensional coronary angiography provides limited information about lesion characteristics, while intravascular ultrasound (IVUS) provides unique and more accurate information regarding neointimal hyperplasia (NIH), vessel remodeling, and stent apposition [ 2 ]. (kjim.org)
  • Acute absolute recoil, assessed by quantitative coronary angiography, was defined as the difference between mean diameter of the last inflated balloon at the highest pressure (X) and mean lumen diameter of the stent immediately after the last balloon deflation (Y). Acute percent recoil was defined as (X - Y)/X and expressed as a percentage. (biomedsearch.com)
  • Fractal geometry of arterial coronary bifurcations: a quantitative coronary angiography and intravascular ultrasound analysis. (springer.com)
  • Transradial versus transfemoral approach for diagnostic coronary angiography and percutaneous coronary intervention in people with coronary artery disease. (bioportfolio.com)
  • The present study enrolled 2312 patients with type 2 diabetes mellitus who underwent percutaneous coronary intervention from January 2013 to December 2014 and who were followed up by angiography. (springer.com)
  • Coronary angiography (Figure 1A) and intravascular ultrasound (IVUS) (Figure 2A) images post procedure show a well apposed stent to the vessel wall, with a good result. (invasivecardiology.com)
  • Follow-up routine coronary angiography performed at 18 months after stenting showed contrast staining outside the stent margin suggestive of incomplete stent apposition (ISA) (Figure 1B). (invasivecardiology.com)
  • We did a single-blind, all-comer superiority trial in adult patients with chronic stable coronary artery disease or acute coronary syndromes, and at least one target lesion. (nih.gov)
  • OBJECTIVES The aim of the present study was to evaluate vascular healing of the bioengineered COMBO Dual Therapy Stent compared with a cobalt-chromium (CoCr) everolimus-eluting stent (EES) as assessed by optical coherence tomography in patients with acute coronary syndromes. (uzh.ch)
  • While it is generally accepted that coronary revascularisation reduces the risk of death and myocardial infarction compared with initial medical treatment among patients with acute coronary syndromes, 1 2 the prognostic benefit is less well established among patients with stable coronary artery disease. (bmj.com)
  • Along with newer antithrombotic therapy using glycoprotein IIb/IIIa platelet inhibitors, stents are used frequently in the management of acute coronary syndromes. (cmaj.ca)
  • New advances in the management of acute coronary syndromes: 3. (cmaj.ca)
  • Acute coronary syndromes (ACS) are a set of ischemic cardiac conditions caused by stenosed coronary arteries, including unstable angina and myocardial infarctions (Table 1). (pharmacytimes.com)
  • Antithrombotic therapy increases the risk of bleeding, which is a notorious complication in the treatment of acute coronary syndromes (ACS) and associated with worse prognosis. (medpagetoday.com)
  • Drug diffusion and biological responses of arteries using a drug-eluting stent with nonuniform coating. (terumo-europe.com)
  • In arteries that had been implanted with SES for 4 M, the stent struts were focally covered by thin membranous tissue mainly composed of fibrin deposition. (ahajournals.org)
  • Methods In May 2007, 15 patients with single de novo lesion located in native coronary arteries 3.0 to 3.5 mm in diameter and ≤14 mm in length were consecutively enrolled. (onlinejacc.org)
  • Scaling of myocardial mass to flow and morphometry of coronary arteries. (springer.com)
  • In its letter to physicians, the manufacturer notes that some cardiologists may be inappropriately inserting the stents, mainly by overexpanding narrower stents so that they will fit in arteries with larger diameters. (cmaj.ca)
  • Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina. (medscape.com)
  • Trials involving stents in nonnative coronary arteries were excluded. (acpjc.org)
  • 50% (by subjective angiographic determination of the minimal luminal diameter compared to the distal reference diameter) within a native coronary artery which has previously undergone stent placement ( 4 weeks). (clinicaltrials.gov)
  • Case selection was based on the availability of IVUS and quantitative coronary angiographic (QCA) examinations at the index procedure and at follow-up. (kjim.org)
  • Primary endpoint was 9 month angiographic in-stent late lumen loss and the secondary endpoint was the occurrence of major adverse events (MACE) through 5-year follow-up. (nih.gov)
  • Methods and results: This randomised, multicentre, single-blinded, non-inferiority trial compared the BuMA Supreme SES versus a contemporary durable polymer zotarolimus-eluting stent (ZES) in terms of angiographic in-stent late lumen loss (LLL) at nine-month follow-up as the primary endpoint. (eur.nl)
  • At nine-month angiographic follow-up, in-stent LLL was 0.29±0.33 mm in the SES group and 0.14±0.37 mm in the ZES group (pnon-inferiority=0.45). (eur.nl)
  • Pushing the boundaries of science and medical engineering for the improvement of health: Ultimaster combines an optimal balance between stent design for ultimate conformability with simultaneous polymer resorption and drug release, to match the procedure-triggered biological response in the vessel. (terumo-europe.com)
  • However, unusual vessel responses to SES, such as late-acquired incomplete stent apposition (ISA) have been observed, and the precise mechanism of late ISA has not been clarified. (ahajournals.org)
  • In saphenous vein graft or ectatic coronary artery disease due to large vessel diameter their use is precluded. (bmj.com)
  • Impact of diabetes mellitus on vessel response in the drug-eluting stent era: pooled volumetric intravascular ultrasound analyses. (semanticscholar.org)
  • At follow-up, no significant differences were observed in the vessel, plaque, or stent volume indices between the two groups. (kjim.org)
  • The purpose of this study was to evaluate the strategy of exclusive use of two SESs versus the combination of one BMS and one SES for two-vessel coronary artery disease (CAD). (elsevier.com)
  • Thereafter, both CAG and IVUS showed optimal stent expansion and apposition to the vessel wall ( Fig. 1C and 1D ). (kjim.org)
  • At the ostium of the LM, implanted stents might be affected by perpendicular shear stress caused by blood flow or mechanical forces due to vessel movement during the cardiac cycle. (kjim.org)
  • Coronary stents are generally indicated to increase coronary vessel diameter in the setting of ischemia due to coronary blockage, either by a combination of acute recoil, arterial contraction of a previously treated segment, and/or local neointimal hyperplasia. (medscape.com)
  • The first balloon expandable stents were designed from surgical grade stainless steel, and aimed to provide additional mechanical support, limiting vessel recoil and preventing acute occlusion [ 6 ]. (mdpi.com)
  • In the stented population, smaller vessel size was associated with a higher stent:vessel ratio, a greater relative gain and a greater subsequent loss index, and a higher risk of adverse cardiac events. (biomedsearch.com)
  • 1. Match the stent size as closely as possible to vessel diameter. (cmaj.ca)
  • 4. Use proper technique to ensure that the stent is fully deployed and in contact with the vessel wall. (cmaj.ca)
  • Undersizing the stent exaggerated the decrease in WSS, increase in WSSG and OSI, and disturbed the flow between the struts and the vessel wall. (royalsocietypublishing.org)
  • A recent study found that stenting of MB lowered WSS on vessel wall, especially downstream of the bifurcation [ 13 ]. (royalsocietypublishing.org)
  • Correct-sized as well as 5 and 10 per cent under-sized stent models (diameters sized relative to vessel diameter of 3 mm) were created for the simulations. (royalsocietypublishing.org)
  • IVUS (Figure 2B) shows ISA, as there is a clear separation seen between stent struts and vessel wall, with an overall dilated vessel compared to the post-procedure IVUS. (invasivecardiology.com)
  • This phenomenon is due to several reported factors: delayed vascular healing of the vessel, positive arterial remodeling and dissolution of the thrombus between the stent and the vessel wall.2,3 Long-term antiplatelet therapy seems logical in these cases, but is still debated. (invasivecardiology.com)
  • Safety and effectiveness of the self-aPposing, bAlloon-delivered, siRolimus-eluting stent for the Treatment of the coronary Artery disease: SPARTA, a multicenter experience. (bioportfolio.com)
  • The impact of proximal cell rewiring compared with distal cell rewiring with single-stent deployment and subsequent kissing balloon inflation in the inadequate jailing of a Kaname stent on the side branch ostium. (semanticscholar.org)
  • Drug-eluting stents (DES) are balloon-mounted, expandable, slotted tubular or multilink scaffolds constructed of a stainless steel or cobalt chromium matrix. (medscape.com)
  • In Protected content , Alvimedica moved their production to a state-of-the-art factory with its own laser-cutting for balloon expandable stents and extrusion capacity for PTCA balloon catheters. (internations.org)
  • Having the biggest Cleanroom in Europe, Alvimedica can do everything from A to Z in the manufacturing of the Stents and PTCA balloon catheters. (internations.org)
  • Sirolimus- versus paclitaxel-eluting stents for the treatment of coronary bifurcations results: from the COBIS (Coronary Bifurcation Stenting) Registry. (semanticscholar.org)
  • Sirolimus-eluting and paclitaxel-eluting stents for the treatment of coronary bifurcations. (semanticscholar.org)
  • The aim of this study is to evaluate the differences of chronic vascular response in patients with diabetes mellitus (DM) following coronary stenting between sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES) using optical coherence tomography (OCT). Methods: We examined non-restenotic 60 SESs and 60 PESs were imaged with motorized OCT pull-back system (1 mm/s) at 9-month follow-up and analyzed at interval of 1 mm. (octnews.org)
  • Of the 1,754 all-comer patients, 1,509 patients (EES 311, sirolimus-eluting stent [SES] 642, paclitaxel-eluting stent 556) were finally analyzed after excluding 245 patients (mixed DESs in 46 and follow-up loss in 199). (elsevier.com)
  • In the inverse probability weighting-adjusted population, the 1-year MACE rate of the EES was comparable with that of the SES (5.8% vs 3.4%, p = 0.796) and the paclitaxel-eluting stent (5.8% vs 6.9%, p = 0.740). (elsevier.com)
  • Until recently, two types of drug-eluting stents have been available: sirolimus- or paclitaxel-eluting stents. (mja.com.au)
  • Boston Scientific makes the Taxus stent that is coated with Paclitaxil (Paclitaxel-Eluting Coronary stent). (healingwell.com)
  • Recently, the relative efficacies of sirolimua-eluting stent (SES) and paclitaxel-eluting stent (PES) in patients with DM have been evaluated in randomized and registry studies (6-10). (bioportfolio.com)
  • Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. (acc.org)
  • Randomized controlled trials (RCTs) that compared DESs (using sirolimus or paclitaxel) with BMSs in patients with coronary artery disease and reported mortality after a follow-up of ≥ 1 year. (acpjc.org)
  • 17 RCTs ( n = 8221) (mean age range 56 to 67 y, 56% to 89% men) met the selection criteria: 8 RCTs ( n = 3032) using sirolimus DESs and 10 RCTs ( n = 5470) using paclitaxel DESs (1 RCT used both). (acpjc.org)
  • Treatment effect for these outcomes did not differ between trials using sirolimus or paclitaxel DESs. (acpjc.org)
  • this increase was observed in 5 RCTs using sirolimus DESs (odds ratio [OR] 2.7, 95% CI 1.2 to 6.1) but not in 7 RCTs using paclitaxel DESs (OR 1.2, CI 0.6 to 2.5). (acpjc.org)
  • One-year cardiovascular outcomes of drug-eluting stent versus bare-metal stent implanted in diabetic patients with acute coronary syndrome. (semanticscholar.org)
  • We evaluated the effectiveness and safety of a zotarolimus-eluting (ZES) versus a sirolimus-eluting (SES) coronary stent in a large cohort of patients treated with one of these stents in Western Denmark. (biomedcentral.com)
  • Several studies have shown the efficacy of sirolimus-eluting stents in selected groups of patients. (clinicaltrials.gov)
  • This study provides preliminary evidence for the feasibility, safety, and efficacy of the Supraflex sirolimus-eluting stent. (hindawi.com)
  • Objectives We sought to investigate the performance and efficacy of the third-generation polymer-free Vestasync-eluting stent (VES). (onlinejacc.org)
  • The aim of this study was to determine the long-term safety and efficacy of the sirolimus-eluting stent (SES) when compared with the bare metal stent (BMS) in patients included in the DIABETES (DIABETes and sirolimus Eluting Stent) trial. (semanticscholar.org)
  • For the treatment of chronic total occlusion (CTO), the efficacy and safety of the everolimus-eluting stent (EES) remain less well defined. (elsevier.com)
  • To evaluate the long-term safety and efficacy of the novel combined sirolimus-eluting endothelial progenitor cell capture Combo stent (OrbusNeich, Fort Lauderdale, FL) at 5 years in the REMEDEE (Randomized study to Evaluate the safety and effectiveness of an abluMinal sirolimus coated bio-Engineered stEnt) trial. (nih.gov)
  • 3, and 44% presented with acute coronary syndrome or myocardial infarction. (elsevier.com)
  • Coronary artery bypass grafting reduced the risk of myocardial infarction compared with medical treatment (0.79, 0.63 to 0.99), and everolimus eluting stents showed a trend towards a reduced risk of myocardial infarction (0.75, 0.55 to 1.01). (bmj.com)
  • Conclusion Among patients with stable coronary artery disease, coronary artery bypass grafting reduces the risk of death, myocardial infarction, and subsequent revascularisation compared with medical treatment. (bmj.com)
  • However, data from a Swedish registry of all patients undergoing coronary stenting between 2003 and 2005 ( n = 39 432) suggest an increased rate of death and myocardial infarction of 0.5%-1.0% per annum with DES, compared with BMS. (mja.com.au)
  • Kassab GS, Finet G. Anatomy and function relation in the coronary tree: from bifurcations to myocardial flow and mass. (springer.com)
  • Both drug-eluting stents were also equivalent in terms of major adverse cardiac events (MACE), which in this study were defined to include cardiac deaths, Q-wave myocardial infarctions, non-Q wave myocardial infarctions, emergent bypass surgery and target lesion revascularizations (a subsequent procedure to reopen an artery). (webwire.com)
  • A silent electrocardiogram in a patient with chest pain and prior stent does not rule-out an acute coronary syndrome, since a myocardial infarction in the circumflex territory may not result in ischemic changes. (oncologynurseadvisor.com)
  • Cordis has been a leader in establishing many markets including diagnostic and guiding catheters, bare metal and drug-eluting stents, carotid stenting, and treatment of peripheral vascular disease and arrhythmias. (mdtmag.com)
  • The business will focus on access, diagnostic and therapeutic products for cardiology procedures, products to diagnose, access and treat lower extremity disease, and the INCRAFT™ Stent-Graft System, the company's new investigational device for treating abdominal aortic aneurysm (AAA). (fiercepharma.com)
  • This was a prospective, nonrandomized, multicenter, single-arm study that enrolled 189 patients with de novo coronary artery disease who were treated with the Supraflex SES. (hindawi.com)
  • Real-World Dual Antiplatelet Therapy Following Polymer-Free Sirolimus-Eluting Stent Implantations to Treat Coronary Artery Disease. (bioportfolio.com)
  • Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. (naver.com)
  • Sirolimus, also known as rapamycin, is a macrolide compound that is used to coat coronary stents, prevent organ transplant rejection and treat a rare lung disease called lymphangioleiomyomatosis. (wikipedia.org)
  • On 28 May 2015, the FDA approved sirolimus to treat lymphangioleiomyomatosis (LAM), a rare, progressive lung disease that primarily affects women of childbearing age. (wikipedia.org)
  • This made sirolimus the first drug approved to treat this disease. (wikipedia.org)
  • Objective To investigate whether revascularisation improves prognosis compared with medical treatment among patients with stable coronary artery disease. (bmj.com)
  • Cardiovascular disease is the dominant cause of mortality in developed countries, with coronary artery disease (CAD) a predominant contributor. (mdpi.com)
  • Cardiovascular disease continues to be the leading cause of mortality [ 1 , 2 ], with a vast majority of these deaths attributed to obstructive coronary artery disease (CAD) [ 3 ]. (mdpi.com)
  • Following recent successes with percutaneous coronary intervention (PCI) for treating coronary artery disease (CAD), many challenges remain. (pnas.org)
  • Diabetic patients remain one of the most complex patient populations to treat for coronary artery disease, said David E. Kandzari, M.D., F.A.C.C., F.S.C.A.I., Chief Medical Officer, Cordis Corporation. (webwire.com)
  • Patients were eligible if they had disease of a native coronary artery (i.e., those with diseased grafts were excluded) in the setting of stable or unstable angina, or silent ischemia. (cmaj.ca)
  • Coronary artery disease (CAD) contributes to half of mortalities caused by CVD. (bioportfolio.com)
  • Historical Milestones in the Management of Stable Coronary Artery Disease over the Last Half Century. (bioportfolio.com)
  • PCI (percutaneous coronary intervention) now outnumbers CABG (coronary artery bypass grafting) by more than 3:1 for the treatment of coronary heart disease. (portlandpress.com)
  • Instability of the plaque atheroma so as to cause the disease to present is also viewed as an inflammatory process, predominantly where plaque macrophages destabilize the cap of the atheroma, resulting in the formation of an intra-coronary thrombus. (portlandpress.com)
  • Subjects with coronary artery disease (CAD) who undergo an on-label percutaneous coronary intervention (PCI) with a placed Orsiro stent within the prior 24 hours will be screened post-index procedure per the protocol inclusion and exclusion criteria. (centerwatch.com)
  • A large, multi-center heart disease prevention study, part of the Women's Health Initiative (WHI), found that estrogen-alone hormone therapy had no effect on coronary heart disease risk but increased the risk of stroke for postmenopausal women. (news-medical.net)
  • Types of CVD include coronary heart disease, hypertension, dyslipidemia and stroke - stroke is now the third leading cause of death, and the leading cause of disability in the western world (source: American Heart Association, AHA). (marketpublishers.com)
  • To assess the long-term outcomes of patients treated with sirolimus-eluting Stentys stent in a real-life setting. (bioportfolio.com)
  • Drug-eluting stents (DES) are now the primary choice for percutaneous coronary interventions - implanted in millions of patients [1] and costing billions of dollars [2] . (plos.org)
  • Since stenting of MB only (a single stent approach) is currently the most common treatment of percutaneous coronary interventions (PCIs) at bifurcations (approx. (royalsocietypublishing.org)
  • Stent lumen and stent obstruction volume by intravascular ultrasound (IVUS) at post-procedure and six months in a subset of patients conducted at 5-7 investigational centers. (clinicaltrials.gov)
  • Serial quantitative intravascular ultrasound and computer-assisted grayscale value analysis for plaque composition over four years were obtained in 23 event-free patients treated with sirolimus-eluting stents. (onlinejacc.org)
  • Methods Serial quantitative intravascular ultrasound and computer-assisted grayscale value analysis over four years were performed in 23 event-free patients treated with sirolimus-eluting stents. (onlinejacc.org)
  • Prediction of the localization of high-risk coronary atherosclerotic plaques on the basis of low endothelial shear stress: an intravascular ultrasound and histopathology natural history study. (springer.com)
  • The only difference between the groups related to the nominal diameter of stent utilized, which was smaller in the SES group than the bare stent group. (nih.gov)
  • Coronary stents have evolved from bare metal compositions, to incorporate advances in pharmacological therapy in what are now known as drug eluting stents (DES). (mdpi.com)
  • Patients were treated at one of five percutaneous coronary intervention centres between January, 2006, and August, 2007. (nih.gov)
  • Intervention: More MACE with zotarolimus-eluting stents than with sirolimus-eluting stents. (nih.gov)
  • Despite recent advances in drug-eluting stent (DES) technology, late adverse events remain concerns after percutaneous coronary intervention. (bioportfolio.com)
  • Positive vascular remodeling after percutaneous coronary intervention (PCI) using drug-eluting stents may be associated to a high dose of an anti-proliferative agent and/or local toxicity of the synthetic polymer. (scielo.br)
  • Percutaneous coronary intervention in patients with a history of previous coronary artery bypass grafting (CABG) is associated with an increased rate of subsequent adverse events compared to those without prior CABG. (nih.gov)
  • The utilization of the sirolimus-eluting stent for percutaneous intervention in a high-risk population with a history of previous CABG surgery is associated with a significant reduction in the rate of major adverse cardiac events at 1 year. (nih.gov)
  • We reported a case of 69 years old man with rare early and complex DES fractures on right coronary that caused acute coronary syndrome 36 hr after a previous percutaneous coronary intervention. (ovid.com)
  • The outperformance of the ultrathin, bioresorbable polymer sirolimus-eluting stent over the durable polymer everolimus-eluting stent in a complex patient population undergoing percutaneous coronary intervention suggests a new direction in improving next generation drug-eluting stent technology. (doctorportal.com.au)
  • The WDHR contains patient- and procedure-specific information on coronary interventions performed at the three coronary intervention centers in Western Denmark (Aarhus University Hospital, Skejby, Aarhus University Hospital, Aalborg, and Odense University Hospital). (biomedcentral.com)
  • The sirolimus is formulated in a polymer coating that affords controlled release through the healing period following coronary intervention. (wikipedia.org)
  • 70%), we focused the study on this type of intervention (single MB stent approach) [ 3 ]. (royalsocietypublishing.org)
  • Remarkable loss of medial SMCs was evident not only at the sites of the stent struts that had contacted and focally compressed the medial layer, but also at the sites where there was bowing of the media into the intima between the struts. (ahajournals.org)
  • Finally, the introduction of dedicated stents for different types of bifurcations, with specific stent designs to provide good deliverability, secured access to the side branch, complete coverage of the lesion site without double/triple layers of stent struts, thus incorporating the benefits of drug elution and ensuring drug availability to all diseased surfaces, may further facilitate the conquest of one of the most challenging areas in interventional cardiology. (dovepress.com)
  • Shrinking of plaque behind the stent struts associated with an increase in echogenicity was observed at four-year follow-up. (onlinejacc.org)
  • Background Sirolimus-eluting stents are effective in inhibiting neointimal hyperplasia without affecting plaque volume behind the stent struts at six months. (onlinejacc.org)
  • Results In the first two years, the mean plaque volume (155.5 ± 42.8 mm 3 post-procedure and 156.8 ± 57.7 mm 3 at two years, p = 0.86) and plaque compositional change expressed as mean percent hypoechogenic tissue of the plaque behind the stent struts (78.9 ± 8.6% post-procedure and 78.2 ± 8.9% at two years, p = 0.67) did not significantly change. (onlinejacc.org)
  • The primary endpoint was the percentage of uncovered stent struts per stent. (uzh.ch)
  • Neointimal coverage of stent struts and the incidence of stent malapposition were evaluated. (octnews.org)
  • Both these drugs have a potent antiproliferative action and are embedded in a non-resorbable polymer matrix completely covering the stent struts, thus allowing slow release of the drug in high concentrations to the local surrounding tissue. (mja.com.au)
  • The presumed cause is delayed or incomplete endothelialization of the stent struts. (acpjc.org)
  • OCT (Figures 3A, 3B) images showed malapposed stent struts, peristrut ulcerations, poor endothelialization of the stent struts, fibrin and microthrombi. (invasivecardiology.com)
  • CAS images (Figure 4A-4D) revealed some exposed stent struts, visible stent struts and red thrombi in between the stent struts. (invasivecardiology.com)
  • Coronary artery bypass grafting was associated with a survival benefit (rate ratio 0.80, 95% credibility interval 0.70 to 0.91) compared with medical treatment. (bmj.com)
  • DESs have dramatically decreased the need for coronary artery bypass graft (CABG) surgery and repeated PCI. (acpjc.org)
  • BRIDGEWATER, N.J., June 15, 2011 /PRNewswire-FirstCall/ -- Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, today announced it will no longer pursue the development of the NEVO™ Sirolimus-Eluting Coronary Stent in order to focus on other cardiovascular therapies where significant patient need exists. (mdtmag.com)
  • Mastering rapid and healthy coronary vascular repair. (terumo-europe.com)
  • The aim of the present study was to characterize the systemic response of biomarkers known to be involved in the vascular response to coronary stenting and determine if oral sirolimus has any effect on the behavior of these biomarkers. (scielo.br)
  • Cordis Corporation has entered into an exclusive worldwide license with Wyeth for the localized delivery of sirolimus in certain fields of use, including delivery via vascular stenting. (bio-medicine.org)
  • There was no linear relationship between increasing sirolimus doses and positive vascular remodeling, suggesting this vascular event may be related to the presence of a synthetic polymer. (scielo.br)
  • Simulations predicted extensive flow-mediated drug delivery in bifurcated vascular beds where the drug distribution patterns are heterogeneous and sensitive to relative stent position and luminal flow. (plos.org)
  • The use of DES in arterial bifurcations requires a complex calculus that balances vascular and stent geometry as well as luminal flow. (plos.org)
  • No drug polymer coating on parts of the stent that experience the most physical stress. (terumo-europe.com)
  • The objective of this post hoc analysis was to analyze real-world dual antiplatelet therapy (DAPT) regimens following polymer-free sirolimus-eluting stent (PF-SES) implantations in an unselected patie. (bioportfolio.com)
  • and group 3, VESTAsync TM (2.9 µg sirolimus/mm, polymer-free sirolimus-eluting stent). (scielo.br)
  • Newly developed, the VES combines a stainless steel platform with a nanothin-microporous hydroxyapatite surface coating impregnated with a polymer-free sirolimus formulation (55 μm). (onlinejacc.org)
  • BACKGROUND: The bioabsorbable everolimus-eluting coronary stent (BVS) is composed of a poly-L-lactic acid backbone, coated with a bioabsorbable polymer containing the antiproliferative drug, everolimus, and expected to be totally metabolized and absorbed in the human body. (biomedsearch.com)
  • Because the BVS is made from polymer, it may have more acute recoil than metallic stents in vivo. (biomedsearch.com)
  • Micell Technologies (Durham, NC) is releasing its flagship product, the MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System, in the European market. (medgadget.com)
  • The technology relies on Micell's patented supercritical fluid technology that allows the drug together with the polymer to stick to the metal stent. (medgadget.com)
  • The rapidly absorbable coating of the MiStent SES is intended to precisely and consistently provide for local drug delivery and limit the duration of polymer exposure, thereby potentially reducing the safety risks associated with current commercially available drug-eluting stents. (medgadget.com)
  • The MiStent SES includes a proprietary stent coating that contains crystalline drug (sirolimus) and an absorbable polymer. (medgadget.com)
  • The coating provides controlled and sustained release of therapeutic levels of drug as the polymer disperses from the stent into the adjacent tissue. (medgadget.com)
  • These properties are intended to enhance safety as compared to conventional permanent polymer drug-eluting stents. (medgadget.com)
  • diabetic patients with a de novo native coronary lesion, as compared to single dose sirolimus-eluting Bx VELOCITY™ stents. (bioportfolio.com)
  • From March 2003 to March 2004, 102 consecutive patients with de novo unprotected LMCA stenoses underwent elective SES stenting (SES group). (onlinejacc.org)
  • Drug-eluting stents, especially those with sirolimus, may increase the risk for noncardiac mortality after the first year. (acpjc.org)
  • Due to evolving market dynamics in the drug-eluting stent (DES) business, we see greater opportunities to benefit patients and grow our business in other areas of the cardiovascular device market," said Seth Fischer, Company Group Chair and Worldwide Chairman, Cordis Corporation. (mdtmag.com)
  • The FTC will make B. Scientific sell the Cordis stent making capability to another company. (healingwell.com)
  • 14. The apparatus of claim 1 , wherein the detected analyte in the blood sample is selected from the group consisting of cardiac enzymes, cardiovascular stent coatings, poisons, prescription drugs, illicit drugs, hormones, steroids, and combinations thereof. (google.com)
  • Primary end points included in-stent late lumen loss and in-stent percent of obstruction at 4 months. (onlinejacc.org)
  • The primary endpoint was in-stent late lumen loss (LLL) at 9-month follow-up. (eur.nl)
  • The type of lesion being treated and lesion morphology also influence healing after treatment with DES and can contribute to ST. Second-generation DES such as the XIENCE V everolimus-eluting stent differ from the first-generation stents with respect to antiproliferative agents, coating technologies, and stent frame. (hindawi.com)
  • Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials. (biomedsearch.com)
  • The primary endpoint was met by 4.7% (55/1,172) of patients assigned to everolimus-eluting stents, 4.7% (55/1,169) assigned to sirolimus-eluting stents and 5.4% (63/1,173) assigned to zotarolimus-eluting stents. (crf.org)
  • Second generation drug-eluting stents (everolimus-eluting and zotarolimus-eluting) appear to have an enhanced safety profile since very late events are very uncommon with these devices. (oncologynurseadvisor.com)
  • Taxus Stent: 1,704 patients). (bio-medicine.org)
  • At 5-year follow-up, the Combo stent remained clinically safe and effective with an overall low rate of MACE comparable to Taxus. (nih.gov)
  • Improvements in stent structure have resulted in a more complete endothelialization, thereby decreasing the incidence of ST. Bioresorbable scaffolds show promise for restoring vasomotor function and minimizing rates of very late ST. Post-PCI treatment with aspirin and clopidogrel for a year is currently the standard of care for DES, but high-risk patients may benefit from more potent antiplatelet agents. (hindawi.com)
  • While a reliable and permanent solution for ST has remained elusive so far, considerable progress has been made in decreasing its incidence through optimal deployment techniques, improved stent design, and effective antiplatelet therapies. (hindawi.com)
  • Few studies have prospectively examined the incidence and consequences of bleeding in unselected patients receiving drug-eluting stents for indications other than ACS, Urban and co-authors continued. (medpagetoday.com)
  • The sirolimus-treated group (SIR-G) comprised 11 patients treated with oral sirolimus one day before and 28 days after stenting and who had been enrolled in a previous study (13). (scielo.br)
  • Complete data sets were available in 94.2% of patients treated with sirolimus-eluting stents and in 94.1% of patients randomized to the control group. (elsevier.com)
  • An Observational Safety Evaluation of Patients Treated With the NEVO Sirolimus-eluting Coronary Stent. (springer.com)
  • We conducted a randomized, double-blind trial comparing a sirolimus-eluting stent with a standard stent in 1058 patients at 53 centers in the United States who had a newly diagnosed lesion in a native coronary artery. (nih.gov)